Identification

Name
Phenobarbital
Accession Number
DB01174  (APRD00184)
Type
Small Molecule
Groups
Approved, Investigational
Description

A barbituric acid derivative that acts as a nonselective central nervous system depressant. It promotes binding to inhibitory gamma-aminobutyric acid subtype receptors, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations. [PubChem]

Structure
Thumb
Synonyms
  • 5-ethyl-5-phenyl-2,4,6(1H,3H,5H)-pyrimidinetrione
  • 5-Ethyl-5-phenyl-pyrimidine-2,4,6-trione
  • 5-Ethyl-5-phenylbarbituric acid
  • 5-ethyl-5-phenylpyrimidine-2,4,6(1H,3H,5H)-trione
  • 5-Phenyl-5-ethylbarbituric acid
  • Phenobarbital
  • Phenobarbitol
  • Phenobarbitone
  • Phenobarbituric Acid
  • Phenylaethylbarbitursaeure
  • Phenylethylbarbiturate
  • Phenylethylbarbituric Acid
  • Phenylethylbarbitursaeure
  • PHENYLETHYLMALONYLUREA
External IDs
NSC-128143 / NSC-9848
Product Ingredients
IngredientUNIICASInChI Key
Phenobarbital sodiumSW9M9BB5K357-30-7WRLGYAWRGXKSKG-UHFFFAOYSA-M
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Barbilixir Elx 4mg/mlElixir4 mgOralD.C. Labs Limited1983-12-312005-07-19Canada
PhenobarbTablet15 mgOralPendopharm Division Of De Pharmascience Inc1957-12-31Not applicableCanada
PhenobarbTablet60 mgOralPendopharm Division Of De Pharmascience Inc1957-12-31Not applicableCanada
PhenobarbTablet30 mgOralPendopharm Division Of De Pharmascience Inc1957-12-31Not applicableCanada
PhenobarbTablet100 mgOralPendopharm Division Of De Pharmascience Inc1957-12-31Not applicableCanada
Phenobarb ElixirElixir5 mgOralPendopharm Division Of De Pharmascience Inc1965-12-31Not applicableCanada
Phenobarbital 100mg TabTablet100 mgOralValeant Canada Lp Valeant Canada S.E.C.1975-12-312009-07-02Canada
Phenobarbital Sodium Injection 120mg/mlSolution120 mgIntramuscular; IntravenousHospira, Inc.1981-12-312012-08-03Canada
Phenobarbital Sodium Injection 30mg/mlSolution30 mgIntramuscular; Intravenous; SubcutaneousHospira, Inc.1981-12-312012-08-03Canada
Phenobarbital Sodium Injection, USPSolution120 mgIntramuscular; IntravenousSandoz Canada Incorporated2008-02-29Not applicableCanada
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Bellergal SpacetabsPhenobarbital (40.0 mg) + Belladonna (0.2 mg) + Ergotamine tartrate (0.6 mg)Tablet, extended releaseOralPaladin Labs Inc1959-01-01Not applicableCanada
Bellergal TabPhenobarbital (20 mg) + Belladonna (.1 mg) + Ergotamine (.3 mg)TabletOralSandoz1951-12-311997-08-12Canada
DiclophenPhenobarbital (15 mg) + Dicyclomine Hydrochloride (10 mg)CapsuleOralPro Doc Limitee1970-12-312009-07-23Canada
Dilantin W Phenobarbital 15mgPhenobarbital (15 mg) + Phenytoin sodium (100 mg)CapsuleOralParke Davis Division, Warner Lambert Canada Inc.1951-12-311999-04-08Canada
Dilantin W Phenobarbital 30mg CapPhenobarbital (30 mg) + Phenytoin sodium (100 mg)CapsuleOralParke Davis Division, Warner Lambert Canada Inc.1969-12-311997-08-25Canada
Donnatal ElixirPhenobarbital (16.2 mg) + Atropine Sulfate (0.0194 mg) + Hyoscyamine sulfate (0.1037 mg) + Scopolamine (6.5 mcg)ElixirOralAyerst Laboratories1991-12-311996-09-10Canada
Donnatal ElixirPhenobarbital (16.2 mg) + Atropine Sulfate (0.0194 mg) + Hyoscyamine sulfate (0.1037 mg) + Scopolamine (6.5 mcg)ElixirOralWyeth Ayerst Canada Inc.1994-12-312001-01-16Canada
Donnatal ExtentabsPhenobarbital (48.6 mg) + Atropine Sulfate (0.0582 mg) + Hyoscyamine sulfate (0.3111 mg) + Scopolamine (0.0195 mg)Tablet, extended releaseOralAyerst Laboratories1991-12-311996-09-10Canada
Donnatal Extentabs SrtPhenobarbital (48.6 mg) + Atropine Sulfate (0.0582 mg) + Hyoscyamine sulfate (0.3111 mg) + Scopolamine (0.0195 mg)Tablet, extended releaseOralWyeth Ayerst Canada Inc.1994-12-312001-05-07Canada
Donnatal TabPhenobarbital (16.2 mg) + Atropine Sulfate (0.0194 mg) + Hyoscyamine sulfate (0.1037 mg) + Scopolamine (6.5 mcg)TabletOralWyeth Ayerst Canada Inc.1994-12-312001-05-22Canada
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
B-DonnaPhenobarbital (16.2 mg/1) + Atropine Sulfate (.0194 mg/1) + Hyoscyamine sulfate (.1037 mg/1) + Scopolamine (.0065 mg/1)TabletOralWinder Laboratories, LLC2015-12-302016-03-11Us
Belladonna Alkaloids with PhenobarbitalPhenobarbital (16.2 mg/1) + Atropine Sulfate (.0194 mg/1) + Hyoscyamine sulfate (.1037 mg/1) + Scopolamine (.0065 mg/1)TabletOralWest Ward Pharmaceutical1966-01-01Not applicableUs0143 114020170720 1564 4ev749
Belladonna Alkaloids with PhenobartbitalPhenobarbital (16.2 mg/1) + Atropine Sulfate (.0194 mg/1) + Hyoscyamine sulfate (.1037 mg/1) + Scopolamine (.0065 mg/1)TabletOralApace Packaging2000-12-012018-03-22Us
Belladonna Alkaloids with PhenobartbitalPhenobarbital (16.2 mg/1) + Atropine Sulfate (.0194 mg/1) + Hyoscyamine sulfate (.1037 mg/1) + Scopolamine (.0065 mg/1)TabletOralLiberty Pharmaceuticals, Inc.2000-12-01Not applicableUs00143 1140 10 nlmimage10 bb045dd2
Belladonna Alkaloids with PhenobartbitalPhenobarbital (16.2 mg/1) + Atropine Sulfate (.0194 mg/1) + Hyoscyamine sulfate (.1037 mg/1) + Scopolamine (.0065 mg/1)TabletOralRebel Distributors2004-08-31Not applicableUs
Belladonna Alkaloids with PhenobartbitalPhenobarbital (16.2 mg/1) + Atropine Sulfate (.0194 mg/1) + Hyoscyamine sulfate (.1037 mg/1) + Scopolamine (.0065 mg/1)TabletOralLegacy Pharmaceutical Packaging2000-12-01Not applicableUs
DonnatalPhenobarbital (16.2 mg/5mL) + Atropine Sulfate (.0194 mg/5mL) + Hyoscyamine sulfate (.1037 mg/5mL) + Scopolamine (.0065 mg/5mL)ElixirOralVista Pharm, Inc.2017-10-26Not applicableUs
DonnatalPhenobarbital (16.2 mg/1) + Atropine Sulfate (.0194 mg/1) + Hyoscyamine sulfate (.1037 mg/1) + Scopolamine (.0065 mg/1)TabletOralAv Kare, Inc.2014-01-06Not applicableUs
DonnatalPhenobarbital (16.2 mg/5mL) + Atropine Sulfate (.0194 mg/5mL) + Hyoscyamine sulfate (.1037 mg/5mL) + Scopolamine (.0065 mg/5mL)ElixirOralPbm Pharmaceuticals Inc.2011-07-01Not applicableUs
DonnatalPhenobarbital (16.2 mg/5mL) + Atropine Sulfate (.0194 mg/5mL) + Hyoscyamine sulfate (.1037 mg/5mL) + Scopolamine (.0065 mg/5mL)ElixirOralPbm Pharmaceuticals Inc.2009-11-01Not applicableUs
International/Other Brands
Luminal
Categories
UNII
YQE403BP4D
CAS number
50-06-6
Weight
Average: 232.2353
Monoisotopic: 232.08479226
Chemical Formula
C12H12N2O3
InChI Key
DDBREPKUVSBGFI-UHFFFAOYSA-N
InChI
InChI=1S/C12H12N2O3/c1-2-12(8-6-4-3-5-7-8)9(15)13-11(17)14-10(12)16/h3-7H,2H2,1H3,(H2,13,14,15,16,17)
IUPAC Name
5-ethyl-5-phenyl-1,3-diazinane-2,4,6-trione
SMILES
CCC1(C(=O)NC(=O)NC1=O)C1=CC=CC=C1

Pharmacology

Indication

For the treatment of all types of seizures except absence seizures.

Associated Conditions
Associated Therapies
Pharmacodynamics

Phenobarbital, the longest-acting barbiturate, is used for its anticonvulsant and sedative-hypnotic properties in the management of all seizure disorders except absence (petit mal).

Mechanism of action

Phenobarbital acts on GABAA receptors, increasing synaptic inhibition. This has the effect of elevating seizure threshold and reducing the spread of seizure activity from a seizure focus. Phenobarbital may also inhibit calcium channels, resulting in a decrease in excitatory transmitter release. The sedative-hypnotic effects of phenobarbital are likely the result of its effect on the polysynaptic midbrain reticular formation, which controls CNS arousal.

TargetActionsOrganism
AGamma-aminobutyric acid receptor subunit alpha-1
potentiator
Human
UNeuronal acetylcholine receptor subunit alpha-4
antagonist
Human
UNeuronal acetylcholine receptor subunit alpha-7
antagonist
Human
UGlutamate receptor 2
antagonist
Human
UGlutamate receptor ionotropic, kainate 2
antagonist
Human
UNMDA receptor
antagonist
Human
UNuclear receptor subfamily 1 group I member 2
activator
Human
Absorption

Absorbed in varying degrees following oral, rectal or parenteral administration. The salts are more rapidly absorbed than are the acids. The rate of absorption is increased if the sodium salt is ingested as a dilute solution or taken on an empty stomach.

Volume of distribution
Not Available
Protein binding

20 to 45%

Metabolism

Hepatic (mostly via CYP2C19).

Route of elimination
Not Available
Half life

53 to 118 hours (mean 79 hours)

Clearance
Not Available
Toxicity

CNS and respiratory depression which may progress to Cheyne-Stokes respiration, areflexia, constriction of the pupils to a slight degree (though in severe poisoning they may wshow paralytic dilation), oliguria, tachycardia, hypotension, lowered body temperature, and coma. Typical shock syndrome (apnea, circulatory collapse, respiratory arrest, and death) may occur.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(2-benzhydryloxyethyl)diethyl-methylammonium iodideThe risk or severity of adverse effects can be increased when Phenobarbital is combined with (2-benzhydryloxyethyl)diethyl-methylammonium iodide.Experimental
(R)-warfarinThe metabolism of (R)-warfarin can be increased when combined with Phenobarbital.Experimental
(S)-WarfarinThe metabolism of (S)-Warfarin can be increased when combined with Phenobarbital.Experimental, Investigational
1,10-PhenanthrolineThe therapeutic efficacy of Phenobarbital can be decreased when used in combination with 1,10-Phenanthroline.Experimental
16-BromoepiandrosteroneThe metabolism of 16-Bromoepiandrosterone can be increased when combined with Phenobarbital.Investigational
2,5-Dimethoxy-4-ethylamphetamineThe serum concentration of Phenobarbital can be decreased when it is combined with 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
2,5-Dimethoxy-4-ethylthioamphetamineThe serum concentration of Phenobarbital can be decreased when it is combined with 2,5-Dimethoxy-4-ethylthioamphetamine.Experimental
3-isobutyl-1-methyl-7H-xanthineThe serum concentration of 3-isobutyl-1-methyl-7H-xanthine can be decreased when it is combined with Phenobarbital.Experimental
3,4-MethylenedioxyamphetamineThe serum concentration of Phenobarbital can be decreased when it is combined with 3,4-Methylenedioxyamphetamine.Experimental, Illicit
3,5-diiodothyropropionic acidThe metabolism of 3,5-diiodothyropropionic acid can be increased when combined with Phenobarbital.Investigational
4-Bromo-2,5-dimethoxyamphetamineThe serum concentration of Phenobarbital can be decreased when it is combined with 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
4-hydroxycoumarinThe metabolism of 4-hydroxycoumarin can be increased when combined with Phenobarbital.Experimental
4-MethoxyamphetamineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with 4-Methoxyamphetamine.Experimental, Illicit
5-androstenedioneThe metabolism of 5-androstenedione can be increased when combined with Phenobarbital.Experimental, Illicit
5-methoxy-N,N-dimethyltryptamineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with 5-methoxy-N,N-dimethyltryptamine.Experimental, Illicit
6-O-benzylguanineThe serum concentration of 6-O-benzylguanine can be decreased when it is combined with Phenobarbital.Investigational
7-DeazaguanineThe serum concentration of 7-Deazaguanine can be decreased when it is combined with Phenobarbital.Experimental
7-NitroindazoleThe risk or severity of adverse effects can be increased when Phenobarbital is combined with 7-Nitroindazole.Experimental
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Experimental
7,9-DimethylguanineThe serum concentration of 7,9-Dimethylguanine can be decreased when it is combined with Phenobarbital.Experimental
8-azaguanineThe serum concentration of 8-azaguanine can be decreased when it is combined with Phenobarbital.Experimental
8-chlorotheophyllineThe serum concentration of 8-chlorotheophylline can be decreased when it is combined with Phenobarbital.Approved
9-DeazaguanineThe serum concentration of 9-Deazaguanine can be decreased when it is combined with Phenobarbital.Experimental
9-MethylguanineThe serum concentration of 9-Methylguanine can be decreased when it is combined with Phenobarbital.Experimental
AbacavirThe serum concentration of Abacavir can be decreased when it is combined with Phenobarbital.Approved, Investigational
AbemaciclibThe serum concentration of Abemaciclib can be decreased when it is combined with Phenobarbital.Approved, Investigational
AbirateroneThe serum concentration of Abiraterone can be decreased when it is combined with Phenobarbital.Approved
AcebutololPhenobarbital may increase the hypotensive activities of Acebutolol.Approved, Investigational
AcefyllineThe serum concentration of Acefylline can be decreased when it is combined with Phenobarbital.Experimental
AcenocoumarolThe metabolism of Acenocoumarol can be increased when combined with Phenobarbital.Approved, Investigational
AcepromazineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Aceprometazine.Approved
AcetaminophenThe metabolism of Acetaminophen can be increased when combined with Phenobarbital.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Acetazolamide.Approved, Vet Approved
AcetohexamideThe metabolism of Acetohexamide can be increased when combined with Phenobarbital.Approved, Investigational, Withdrawn
AcetophenazineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Acetophenazine.Approved
Acetylglycinamide chloral hydrateThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Acetylglycinamide chloral hydrate.Experimental
AclidiniumThe risk or severity of adverse effects can be increased when Aclidinium is combined with Phenobarbital.Approved
AcyclovirThe serum concentration of Acyclovir can be decreased when it is combined with Phenobarbital.Approved
AdinazolamThe metabolism of Adinazolam can be increased when combined with Phenobarbital.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Adipiplon.Investigational
AfatinibThe serum concentration of Afatinib can be decreased when it is combined with Phenobarbital.Approved
AgmatineThe metabolism of Agmatine can be increased when combined with Phenobarbital.Experimental, Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Agomelatine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Alaproclate.Experimental
AlbendazoleThe serum concentration of the active metabolites of Albendazole can be reduced when Albendazole is used in combination with Phenobarbital resulting in a loss in efficacy.Approved, Vet Approved
AlclometasoneThe metabolism of Alclometasone can be increased when combined with Phenobarbital.Approved
AlcuroniumThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Alcuronium.Experimental
AldesleukinPhenobarbital may increase the hypotensive activities of Aldesleukin.Approved
AldosteroneThe metabolism of Aldosterone can be increased when combined with Phenobarbital.Experimental, Investigational
AlectinibThe serum concentration of Phenobarbital can be increased when it is combined with Alectinib.Approved, Investigational
AlfaxaloneThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Alfaxalone.Vet Approved
AlfentanilThe metabolism of Alfentanil can be increased when combined with Phenobarbital.Approved, Illicit
AlfuzosinThe metabolism of Alfuzosin can be increased when combined with Phenobarbital.Approved, Investigational
AlimemazineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Alimemazine.Approved, Vet Approved
AliskirenPhenobarbital may increase the hypotensive activities of Aliskiren.Approved, Investigational
AllobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Allobarbital.Experimental
AllopregnanoloneThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Allopregnanolone.Investigational
AllylestrenolThe metabolism of Allylestrenol can be increased when combined with Phenobarbital.Approved
AlmotriptanThe metabolism of Almotriptan can be increased when combined with Phenobarbital.Approved, Investigational
AlogliptinThe metabolism of Alogliptin can be increased when combined with Phenobarbital.Approved
AlosetronThe metabolism of Alosetron can be increased when combined with Phenobarbital.Approved, Withdrawn
alpha-Tocopherol acetateThe metabolism of alpha-Tocopherol acetate can be increased when combined with Phenobarbital.Approved
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Alphaprodine.Illicit
AlprazolamThe serum concentration of Alprazolam can be decreased when it is combined with Phenobarbital.Approved, Illicit, Investigational
AlprenololThe serum concentration of Alprenolol can be decreased when it is combined with Phenobarbital.Approved, Withdrawn
AlverineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Alverine.Approved, Investigational
AlvocidibThe serum concentration of Alvocidib can be decreased when it is combined with Phenobarbital.Experimental, Investigational
AmantadineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Amantadine.Approved
AmbenoniumThe therapeutic efficacy of Phenobarbital can be decreased when used in combination with Ambenonium.Approved
AmbrisentanThe metabolism of Ambrisentan can be increased when combined with Phenobarbital.Approved, Investigational
AmbroxolThe metabolism of Ambroxol can be increased when combined with Phenobarbital.Approved, Investigational
AmcinonideThe metabolism of Amcinonide can be increased when combined with Phenobarbital.Approved
AmifostinePhenobarbital may increase the hypotensive activities of Amifostine.Approved, Investigational
AmikacinThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Amikacin.Approved, Investigational, Vet Approved
AmiloridePhenobarbital may increase the hypotensive activities of Amiloride.Approved
AmineptineThe metabolism of Amineptine can be increased when combined with Phenobarbital.Illicit, Withdrawn
AminophenazoneThe metabolism of Aminophenazone can be increased when combined with Phenobarbital.Approved, Withdrawn
AminophyllineThe metabolism of Aminophylline can be increased when combined with Phenobarbital.Approved
AmiodaronePhenobarbital may increase the hypotensive activities of Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Amisulpride.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be decreased when it is combined with Phenobarbital.Approved
AmitriptylinoxideThe metabolism of Amitriptylinoxide can be increased when combined with Phenobarbital.Approved, Investigational
AmlodipinePhenobarbital may increase the hypotensive activities of Amlodipine.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Amobarbital.Approved, Illicit
AmodiaquineThe metabolism of Amodiaquine can be increased when combined with Phenobarbital.Approved, Investigational
AmoxapineThe metabolism of Amoxapine can be increased when combined with Phenobarbital.Approved
AmperozideThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Amperozide.Experimental
AmphetamineThe serum concentration of Phenobarbital can be decreased when it is combined with Amphetamine.Approved, Illicit, Investigational
Amphotericin BPhenobarbital may increase the hypotensive activities of Amphotericin B.Approved, Investigational
AmprenavirThe serum concentration of Phenobarbital can be increased when it is combined with Amprenavir.Approved, Investigational
AmsacrineThe serum concentration of Phenobarbital can be increased when it is combined with Amsacrine.Approved, Investigational
Amyl NitritePhenobarbital may increase the hypotensive activities of Amyl Nitrite.Approved
AnagrelideThe metabolism of Anagrelide can be increased when combined with Phenobarbital.Approved
AndrostenedioneThe metabolism of Androstenedione can be increased when combined with Phenobarbital.Experimental, Illicit
AniracetamThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Aniracetam.Experimental
AnisodamineThe serum concentration of Anisodamine can be decreased when it is combined with Phenobarbital.Investigational
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Phenobarbital.Approved
AnnamycinThe serum concentration of Phenobarbital can be increased when it is combined with Annamycin.Investigational
AntipyrineThe metabolism of Antipyrine can be increased when combined with Phenobarbital.Approved, Investigational
ApalutamideThe serum concentration of Phenobarbital can be decreased when it is combined with Apalutamide.Approved, Investigational
APD791The risk or severity of adverse effects can be increased when Phenobarbital is combined with APD791.Investigational
ApixabanThe serum concentration of Apixaban can be decreased when it is combined with Phenobarbital.Approved
ApomorphinePhenobarbital may increase the hypotensive activities of Apomorphine.Approved, Investigational
ApraclonidinePhenobarbital may increase the hypotensive activities of Apraclonidine.Approved
ApramycinThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Apramycin.Experimental, Vet Approved
ApremilastThe serum concentration of Apremilast can be decreased when it is combined with Phenobarbital.Approved, Investigational
AprepitantThe metabolism of Aprepitant can be increased when combined with Phenobarbital.Approved, Investigational
AprobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Aprobarbital.Approved, Illicit
ApronalideThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Apronalide.Experimental
AranidipineThe metabolism of Aranidipine can be increased when combined with Phenobarbital.Approved, Investigational
Arbaclofen PlacarbilThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Arbaclofen Placarbil.Investigational
ArbekacinThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Arbekacin.Approved, Investigational
ArgatrobanThe metabolism of Argatroban can be increased when combined with Phenobarbital.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Phenobarbital.Approved, Investigational
Aripiprazole lauroxilThe serum concentration of aripiprazole, an active metabolite of Phenobarbital, can be decreased when used in combination with Aripiprazole lauroxil.Approved, Investigational
ArmodafinilThe metabolism of Phenobarbital can be decreased when combined with Armodafinil.Approved, Investigational
ArotinololPhenobarbital may increase the hypotensive activities of Arotinolol.Investigational
Arsenic trioxidePhenobarbital may increase the hypotensive activities of Arsenic trioxide.Approved, Investigational
ArtemetherThe serum concentration of the active metabolites of Artemether can be reduced when Artemether is used in combination with Phenobarbital resulting in a loss in efficacy.Approved
AsenapineThe metabolism of Asenapine can be increased when combined with Phenobarbital.Approved
AstemizoleThe metabolism of Astemizole can be increased when combined with Phenobarbital.Approved, Withdrawn
AsunaprevirThe serum concentration of Asunaprevir can be decreased when it is combined with Phenobarbital.Approved, Investigational, Withdrawn
AtazanavirThe serum concentration of Phenobarbital can be increased when it is combined with Atazanavir.Approved, Investigational
AtenololPhenobarbital may increase the hypotensive activities of Atenolol.Approved
AtomoxetineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Atomoxetine.Approved
AtorvastatinThe serum concentration of Atorvastatin can be decreased when it is combined with Phenobarbital.Approved
AtovaquoneThe metabolism of Atovaquone can be increased when combined with Phenobarbital.Approved
AtracuriumThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Atracurium.Approved, Experimental, Investigational
Atracurium besylateThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Atracurium besylate.Approved
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Phenobarbital.Approved, Vet Approved
AvanafilThe metabolism of Avanafil can be increased when combined with Phenobarbital.Approved
AxitinibThe serum concentration of Axitinib can be decreased when it is combined with Phenobarbital.Approved, Investigational
AzaperoneThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Azaperone.Investigational, Vet Approved
AzathioprineThe serum concentration of Azathioprine can be decreased when it is combined with Phenobarbital.Approved
AZD-3043The risk or severity of adverse effects can be increased when Phenobarbital is combined with AZD-3043.Investigational
AzelastinePhenobarbital may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelnidipineThe metabolism of Azelnidipine can be increased when combined with Phenobarbital.Approved, Investigational
Azilsartan medoxomilPhenobarbital may increase the hypotensive activities of Azilsartan medoxomil.Approved, Investigational
AzithromycinThe metabolism of Azithromycin can be increased when combined with Phenobarbital.Approved
BaclofenThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Baclofen.Approved
Bafilomycin A1The serum concentration of Phenobarbital can be increased when it is combined with Bafilomycin A1.Experimental
Bafilomycin B1The serum concentration of Phenobarbital can be increased when it is combined with Bafilomycin B1.Experimental
BalaglitazoneThe metabolism of Balaglitazone can be increased when combined with Phenobarbital.Investigational
BamifyllineThe serum concentration of Bamifylline can be decreased when it is combined with Phenobarbital.Experimental
BanoxantroneThe metabolism of Banoxantrone can be increased when combined with Phenobarbital.Investigational
BarbexacloneThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Barbexaclone.Experimental
BarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Barbital.Illicit
Barbituric acid derivativeThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Barbituric acid derivative.Experimental, Illicit
BaricitinibThe metabolism of Baricitinib can be increased when combined with Phenobarbital.Approved, Investigational
BarnidipineThe serum concentration of Barnidipine can be decreased when it is combined with Phenobarbital.Approved
BazedoxifeneThe serum concentration of Bazedoxifene can be decreased when it is combined with Phenobarbital.Approved, Investigational
BeclamideThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Beclamide.Experimental
Beclomethasone dipropionateThe metabolism of Beclomethasone dipropionate can be increased when combined with Phenobarbital.Approved, Investigational
BedaquilineThe serum concentration of Bedaquiline can be decreased when it is combined with Phenobarbital.Approved
BefunololThe serum concentration of Befunolol can be decreased when it is combined with Phenobarbital.Experimental
BekanamycinThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Bekanamycin.Experimental
BelinostatThe serum concentration of Belinostat can be decreased when it is combined with Phenobarbital.Approved, Investigational
BenactyzineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Benactyzine.Withdrawn
BenazeprilPhenobarbital may increase the hypotensive activities of Benazepril.Approved, Investigational
BencyclaneThe metabolism of Bencyclane can be increased when combined with Phenobarbital.Experimental
BendamustineThe serum concentration of Bendamustine can be decreased when it is combined with Phenobarbital.Approved, Investigational
BendroflumethiazideThe risk or severity of hypotension and orthostatic hypotension can be increased when Phenobarbital is combined with Bendroflumethiazide.Approved
BenidipineThe metabolism of Benidipine can be increased when combined with Phenobarbital.Approved, Investigational
BenmoxinThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Benmoxin.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Benperidol.Approved, Investigational
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Phenobarbital.Approved
BenziloneThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Benzilone.Experimental
BenzoctamineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Benzoctamine.Approved
BenzphetamineThe serum concentration of Phenobarbital can be decreased when it is combined with Benzphetamine.Approved, Illicit
BenzquinamideThe serum concentration of Phenobarbital can be increased when it is combined with Benzquinamide.Withdrawn
BenzthiazideThe risk or severity of hypotension and orthostatic hypotension can be increased when Phenobarbital is combined with Benzthiazide.Approved
BenzydamineThe metabolism of Benzydamine can be increased when combined with Phenobarbital.Approved
Benzyl alcoholThe metabolism of Benzyl alcohol can be increased when combined with Phenobarbital.Approved
BepridilPhenobarbital may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetamethasoneThe metabolism of Betamethasone can be increased when combined with Phenobarbital.Approved, Vet Approved
BetaxololPhenobarbital may increase the hypotensive activities of Betaxolol.Approved, Investigational
BevantololThe serum concentration of Bevantolol can be decreased when it is combined with Phenobarbital.Approved
BevoniumThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Bevonium.Experimental
BexaroteneThe metabolism of Bexarotene can be increased when combined with Phenobarbital.Approved, Investigational
BezafibrateThe metabolism of Bezafibrate can be increased when combined with Phenobarbital.Approved, Investigational
BezitramideThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Bezitramide.Experimental, Illicit, Withdrawn
BicalutamideThe metabolism of Bicalutamide can be increased when combined with Phenobarbital.Approved
BictegravirThe serum concentration of Bictegravir can be decreased when it is combined with Phenobarbital.Approved, Investigational
BifemelaneThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Bifemelane.Experimental
BifeprunoxThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Bifeprunox.Investigational
BinimetinibThe serum concentration of Binimetinib can be decreased when it is combined with Phenobarbital.Approved, Investigational
BioallethrinThe metabolism of Bioallethrin can be increased when combined with Phenobarbital.Approved, Experimental
BiperidenThe risk or severity of adverse effects can be increased when Biperiden is combined with Phenobarbital.Approved, Investigational
Biricodar dicitrateThe serum concentration of Phenobarbital can be increased when it is combined with Biricodar dicitrate.Investigational
BisoprololPhenobarbital may increase the hypotensive activities of Bisoprolol.Approved
BL-1020The risk or severity of adverse effects can be increased when Phenobarbital is combined with BL-1020.Investigational
BlonanserinThe metabolism of Blonanserin can be increased when combined with Phenobarbital.Approved, Investigational
BopindololThe serum concentration of Bopindolol can be decreased when it is combined with Phenobarbital.Approved
BornaprineThe risk or severity of adverse effects can be increased when Bornaprine is combined with Phenobarbital.Experimental
BortezomibThe serum concentration of Bortezomib can be decreased when it is combined with Phenobarbital.Approved, Investigational
BosentanThe metabolism of Bosentan can be increased when combined with Phenobarbital.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be decreased when it is combined with Phenobarbital.Approved
Botulinum Toxin Type AThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Botulinum Toxin Type A.Approved, Investigational
Botulinum Toxin Type BThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Botulinum Toxin Type B.Approved, Investigational
Brefeldin AThe serum concentration of Phenobarbital can be increased when it is combined with Brefeldin A.Experimental
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Phenobarbital.Approved, Investigational
BretyliumPhenobarbital may increase the hypotensive activities of Bretylium.Approved
BrexpiprazoleThe serum concentration of Brexpiprazole can be decreased when it is combined with Phenobarbital.Approved, Investigational
BrigatinibThe metabolism of Brigatinib can be increased when combined with Phenobarbital.Approved, Investigational
BrinzolamideThe metabolism of Brinzolamide can be increased when combined with Phenobarbital.Approved
BrivaracetamThe metabolism of Brivaracetam can be increased when combined with Phenobarbital.Approved, Investigational
BrofaromineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Brofaromine.Experimental
BromazepamThe metabolism of Bromazepam can be increased when combined with Phenobarbital.Approved, Illicit, Investigational
BromisovalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Bromisoval.Experimental
BromocriptinePhenobarbital may increase the hypotensive activities of Bromocriptine.Approved, Investigational
BromotheophyllineThe serum concentration of Bromotheophylline can be decreased when it is combined with Phenobarbital.Approved
BromperidolThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Bromperidol.Approved, Investigational
BrompheniramineThe metabolism of Brompheniramine can be increased when combined with Phenobarbital.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Brotizolam.Approved, Investigational, Withdrawn
BucindololThe serum concentration of Bucindolol can be decreased when it is combined with Phenobarbital.Investigational
BuclizineThe risk or severity of adverse effects can be increased when Buclizine is combined with Phenobarbital.Approved
BudesonideThe metabolism of Budesonide can be increased when combined with Phenobarbital.Approved
BufotenineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Bufotenine.Experimental, Illicit
BufuralolThe serum concentration of Bufuralol can be decreased when it is combined with Phenobarbital.Experimental, Investigational
BufyllineThe serum concentration of Bufylline can be decreased when it is combined with Phenobarbital.Experimental
BumetanidePhenobarbital may increase the hypotensive activities of Bumetanide.Approved
BupivacainePhenobarbital may increase the hypotensive activities of Bupivacaine.Approved, Investigational
BupranololThe serum concentration of Bupranolol can be decreased when it is combined with Phenobarbital.Approved
BuprenorphinePhenobarbital may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Bupropion can be increased when combined with Phenobarbital.Approved
BuspironeThe metabolism of Buspirone can be increased when combined with Phenobarbital.Approved, Investigational
BusulfanThe metabolism of Busulfan can be increased when combined with Phenobarbital.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Phenobarbital.Approved, Illicit
ButalbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Butalbital.Approved, Illicit
ButaperazineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Butaperazine.Experimental
ButethalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Phenobarbital.Approved, Illicit, Vet Approved
ButriptylineThe metabolism of Butriptyline can be increased when combined with Phenobarbital.Approved
ButylscopolamineThe risk or severity of adverse effects can be increased when Butylscopolamine is combined with Phenobarbital.Approved, Investigational, Vet Approved
CabazitaxelThe metabolism of Cabazitaxel can be increased when combined with Phenobarbital.Approved
CabergolineThe metabolism of Cabergoline can be increased when combined with Phenobarbital.Approved
CabozantinibThe serum concentration of Cabozantinib can be decreased when it is combined with Phenobarbital.Approved, Investigational
CafedrineThe serum concentration of Cafedrine can be decreased when it is combined with Phenobarbital.Investigational
CaffeineThe serum concentration of Caffeine can be decreased when it is combined with Phenobarbital.Approved
CalcitriolThe metabolism of Calcitriol can be increased when combined with Phenobarbital.Approved, Nutraceutical
CamazepamThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Camazepam.Approved, Illicit
CamylofinThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Camylofin.Experimental
CanagliflozinThe serum concentration of Canagliflozin can be decreased when it is combined with Phenobarbital.Approved
Candesartan cilexetilPhenobarbital may increase the hypotensive activities of Candesartan cilexetil.Approved
CannabidiolThe serum concentration of Cannabidiol can be decreased when it is combined with Phenobarbital.Approved, Investigational
CannabidivarinThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Cannabidivarin.Investigational
CapreomycinThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Capreomycin.Approved
CaptodiameThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Captodiame.Approved, Investigational
CaptoprilPhenobarbital may increase the hypotensive activities of Captopril.Approved
CarbamazepineThe metabolism of Carbamazepine can be increased when combined with Phenobarbital.Approved, Investigational
CarbetocinPhenobarbital may increase the hypotensive activities of Carbetocin.Approved, Investigational
CarbinoxamineThe metabolism of Carbinoxamine can be increased when combined with Phenobarbital.Approved
CarboxyamidotriazoleThe metabolism of Carboxyamidotriazole can be increased when combined with Phenobarbital.Investigational
CarbromalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Carbromal.Experimental
CarbutamideThe metabolism of Carbutamide can be increased when combined with Phenobarbital.Experimental
CarfentanilThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Carfentanil.Illicit, Investigational, Vet Approved
CariprazineThe metabolism of Cariprazine can be increased when combined with Phenobarbital.Approved, Investigational
CarisbamateThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Carisbamate.Investigational
CarisoprodolThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Carisoprodol.Approved
CaroverineThe metabolism of Caroverine can be increased when combined with Phenobarbital.Experimental
CaroxazoneThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Caroxazone.Withdrawn
CarteololPhenobarbital may increase the hypotensive activities of Carteolol.Approved
CarvedilolThe serum concentration of Carvedilol can be decreased when it is combined with Phenobarbital.Approved, Investigational
CathinoneThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Cathinone.Illicit
CefoperazoneThe serum concentration of Phenobarbital can be increased when it is combined with Cefoperazone.Approved, Investigational
CeftriaxoneThe serum concentration of Phenobarbital can be increased when it is combined with Ceftriaxone.Approved
CelecoxibThe metabolism of Celecoxib can be increased when combined with Phenobarbital.Approved, Investigational
CeliprololThe serum concentration of Celiprolol can be decreased when it is combined with Phenobarbital.Approved, Investigational
CephalexinThe metabolism of Cephalexin can be increased when combined with Phenobarbital.Approved, Investigational, Vet Approved
CeritinibThe serum concentration of Ceritinib can be decreased when it is combined with Phenobarbital.Approved
CerivastatinThe serum concentration of Cerivastatin can be decreased when it is combined with Phenobarbital.Approved, Withdrawn
CerlapirdineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Cerlapirdine.Investigational
CetirizineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Cetirizine.Approved
CevimelineThe metabolism of Cevimeline can be increased when combined with Phenobarbital.Approved
Chenodeoxycholic acidThe metabolism of Chenodeoxycholic acid can be increased when combined with Phenobarbital.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Chloral hydrate.Approved, Illicit, Investigational, Vet Approved
ChloramphenicolThe metabolism of Phenobarbital can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be increased when combined with Phenobarbital.Approved, Illicit, Investigational
ChlormadinoneThe therapeutic efficacy of Chlormadinone can be decreased when used in combination with Phenobarbital.Experimental
ChlormezanoneThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Chlormezanone.Approved, Investigational, Withdrawn
ChloroformThe serum concentration of Phenobarbital can be increased when it is combined with Chloroform.Vet Approved
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Phenobarbital.Approved
ChloroquineThe metabolism of Chloroquine can be increased when combined with Phenobarbital.Approved, Investigational, Vet Approved
ChlorothiazideThe risk or severity of hypotension and orthostatic hypotension can be increased when Phenobarbital is combined with Chlorothiazide.Approved, Vet Approved
ChlorphenamineThe metabolism of Chlorphenamine can be increased when combined with Phenobarbital.Approved
ChlorphenesinThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Chlorphenesin.Approved, Vet Approved, Withdrawn
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Phenobarbital.Withdrawn
ChlorphentermineThe serum concentration of Phenobarbital can be decreased when it is combined with Chlorphentermine.Illicit, Withdrawn
ChlorproethazineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Chlorproethazine.Experimental
ChlorpromazinePhenobarbital may increase the hypotensive activities of Chlorpromazine.Approved, Investigational, Vet Approved
ChlorpropamideThe metabolism of Chlorpropamide can be increased when combined with Phenobarbital.Approved, Investigational
ChlorprothixeneThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Chlorprothixene.Approved, Investigational, Withdrawn
ChlortetracyclineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Chlortetracycline.Approved, Investigational, Vet Approved
ChlorthalidoneThe risk or severity of hypotension and orthostatic hypotension can be increased when Phenobarbital is combined with Chlorthalidone.Approved
ChlorzoxazoneThe metabolism of Chlorzoxazone can be increased when combined with Phenobarbital.Approved
CholecalciferolThe metabolism of Cholecalciferol can be increased when combined with Phenobarbital.Approved, Nutraceutical
CholestyramineThe serum concentration of Phenobarbital can be decreased when it is combined with Cholestyramine.Approved, Investigational
CiclesonideThe metabolism of Ciclesonide can be increased when combined with Phenobarbital.Approved, Investigational
CiglitazoneThe metabolism of Ciglitazone can be increased when combined with Phenobarbital.Experimental
CilansetronThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Cilansetron.Investigational
CilazaprilPhenobarbital may increase the hypotensive activities of Cilazapril.Approved
CilnidipinePhenobarbital may increase the hypotensive activities of Cilnidipine.Approved, Investigational
CilostazolThe metabolism of Cilostazol can be increased when combined with Phenobarbital.Approved, Investigational
CinacalcetThe metabolism of Cinacalcet can be increased when combined with Phenobarbital.Approved
CinitaprideThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Cinitapride.Approved, Investigational
CinnarizineThe metabolism of Cinnarizine can be increased when combined with Phenobarbital.Approved, Investigational
CinolazepamThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Cinolazepam.Approved
CisaprideThe metabolism of Cisapride can be increased when combined with Phenobarbital.Approved, Investigational, Withdrawn
CisatracuriumThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Cisatracurium.Approved
CitalopramThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Citalopram.Approved
ClarithromycinThe serum concentration of the active metabolites of Clarithromycin can be increased when Clarithromycin is used in combination with Phenobarbital.Approved
ClemastineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Clemastine.Approved, Investigational
ClevidipinePhenobarbital may increase the hypotensive activities of Clevidipine.Approved, Investigational
ClidiniumThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Clidinium.Approved
ClindamycinThe metabolism of Clindamycin can be increased when combined with Phenobarbital.Approved, Vet Approved
ClobazamThe metabolism of Clobazam can be increased when combined with Phenobarbital.Approved, Illicit
ClobetasolThe metabolism of Clobetasol can be increased when combined with Phenobarbital.Approved, Investigational
Clobetasol propionateThe metabolism of Clobetasol propionate can be increased when combined with Phenobarbital.Approved
ClobetasoneThe metabolism of Clobetasone can be increased when combined with Phenobarbital.Approved
ClofarabinePhenobarbital may increase the hypotensive activities of Clofarabine.Approved, Investigational
ClofazimineThe metabolism of Clofazimine can be increased when combined with Phenobarbital.Approved, Investigational
ClofibrateThe metabolism of Clofibrate can be increased when combined with Phenobarbital.Approved, Investigational
clomethiazoleThe metabolism of clomethiazole can be increased when combined with Phenobarbital.Investigational
ClomipramineThe metabolism of Clomipramine can be increased when combined with Phenobarbital.Approved, Investigational, Vet Approved
ClomocyclineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Clomocycline.Approved
ClonazepamThe metabolism of Clonazepam can be increased when combined with Phenobarbital.Approved, Illicit
ClonidinePhenobarbital may increase the hypotensive activities of Clonidine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Clopenthixol.Experimental
ClopidogrelThe metabolism of Clopidogrel can be increased when combined with Phenobarbital.Approved
CloranololThe serum concentration of Cloranolol can be decreased when it is combined with Phenobarbital.Experimental
ClorazepateThe metabolism of Clorazepate can be increased when combined with Phenobarbital.Approved, Illicit
ClorindioneThe metabolism of Clorindione can be increased when combined with Phenobarbital.Experimental
ClothiapineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Clothiapine.Experimental
ClotiazepamThe metabolism of Clotiazepam can be increased when combined with Phenobarbital.Approved, Illicit
CloxazolamThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Cloxazolam.Approved, Investigational
ClozapineThe serum concentration of Clozapine can be decreased when it is combined with Phenobarbital.Approved
CobicistatThe serum concentration of Cobicistat can be decreased when it is combined with Phenobarbital.Approved
CobimetinibThe serum concentration of Cobimetinib can be decreased when it is combined with Phenobarbital.Approved, Investigational
CocaineThe metabolism of Cocaine can be increased when combined with Phenobarbital.Approved, Illicit
CodeineThe serum concentration of Codeine can be decreased when it is combined with Phenobarbital.Approved, Illicit
ColchicineThe metabolism of Colchicine can be increased when combined with Phenobarbital.Approved
ColistimethateThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Colistimethate.Approved, Vet Approved
ColistinThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Colistin.Approved
Concanamycin AThe serum concentration of Phenobarbital can be increased when it is combined with Concanamycin A.Experimental
ConivaptanPhenobarbital may increase the hypotensive activities of Conivaptan.Approved, Investigational
Conjugated estrogensThe metabolism of Conjugated estrogens can be increased when combined with Phenobarbital.Approved
CopanlisibThe metabolism of Copanlisib can be increased when combined with Phenobarbital.Approved, Investigational
CorticosteroneThe metabolism of Corticosterone can be increased when combined with Phenobarbital.Experimental
CorticotropinThe metabolism of Corticotropin can be increased when combined with Phenobarbital.Approved, Investigational, Vet Approved
Cortisone acetateThe metabolism of Cortisone acetate can be increased when combined with Phenobarbital.Approved, Investigational
CoumaphosThe therapeutic efficacy of Phenobarbital can be decreased when used in combination with Coumaphos.Vet Approved
CrizotinibThe serum concentration of Crizotinib can be decreased when it is combined with Phenobarbital.Approved
CurcuminThe serum concentration of Phenobarbital can be increased when it is combined with Curcumin.Approved, Investigational
CyamemazineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Cyamemazine.Approved
CyclandelateThe metabolism of Cyclandelate can be increased when combined with Phenobarbital.Approved
CyclizineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Cyclizine.Approved
CyclobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Cyclobarbital.Experimental
CyclobenzaprineThe serum concentration of Cyclobenzaprine can be decreased when it is combined with Phenobarbital.Approved
CyclopenthiazideThe risk or severity of hypotension and orthostatic hypotension can be increased when Phenobarbital is combined with Cyclopenthiazide.Experimental
CyclopentolateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Phenobarbital.Approved
CyclophosphamideThe metabolism of Cyclophosphamide can be increased when combined with Phenobarbital.Approved, Investigational
CyclopropaneThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Cyclopropane.Experimental
CyclosporineThe metabolism of Cyclosporine can be increased when combined with Phenobarbital.Approved, Investigational, Vet Approved
CycrimineThe risk or severity of adverse effects can be increased when Cycrimine is combined with Phenobarbital.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Cyproheptadine.Approved
Cyproterone acetateThe therapeutic efficacy of Cyproterone acetate can be decreased when used in combination with Phenobarbital.Approved, Investigational
CytarabineThe metabolism of Cytarabine can be increased when combined with Phenobarbital.Approved, Investigational
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Phenobarbital.Approved
DabrafenibThe serum concentration of Phenobarbital can be decreased when it is combined with Dabrafenib.Approved, Investigational
DacarbazineThe metabolism of Dacarbazine can be increased when combined with Phenobarbital.Approved, Investigational
DaclatasvirThe serum concentration of Daclatasvir can be decreased when it is combined with Phenobarbital.Approved, Investigational
DactinomycinThe serum concentration of Phenobarbital can be increased when it is combined with Dactinomycin.Approved, Investigational
DantroleneThe metabolism of Dantrolene can be increased when combined with Phenobarbital.Approved, Investigational
DapagliflozinPhenobarbital may increase the hypotensive activities of Dapagliflozin.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Dapiprazole.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Dapoxetine.Investigational
DapsoneThe risk or severity of adverse effects can be increased when Dapsone is combined with Phenobarbital.Approved, Investigational
DarifenacinThe metabolism of Darifenacin can be increased when combined with Phenobarbital.Approved, Investigational
DarodipineThe metabolism of Darodipine can be increased when combined with Phenobarbital.Experimental
DarunavirThe serum concentration of Phenobarbital can be decreased when it is combined with Darunavir.Approved
DasabuvirThe serum concentration of Dasabuvir can be decreased when it is combined with Phenobarbital.Approved
DasatinibThe serum concentration of Dasatinib can be decreased when it is combined with Phenobarbital.Approved, Investigational
DaunorubicinThe metabolism of Daunorubicin can be increased when combined with Phenobarbital.Approved
DeanolThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Deanol.Experimental
DecamethoniumThe therapeutic efficacy of Phenobarbital can be decreased when used in combination with Decamethonium.Approved
DeferasiroxThe serum concentration of Deferasirox can be decreased when it is combined with Phenobarbital.Approved, Investigational
DeflazacortThe metabolism of Deflazacort can be increased when combined with Phenobarbital.Approved, Investigational
DelafloxacinThe serum concentration of Delafloxacin can be decreased when it is combined with Phenobarbital.Approved, Investigational
DelamanidThe metabolism of Delamanid can be increased when combined with Phenobarbital.Approved, Investigational
DelavirdineThe metabolism of Delavirdine can be increased when combined with Phenobarbital.Approved
DelorazepamThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Delorazepam.Approved, Illicit, Investigational
DemecariumThe therapeutic efficacy of Phenobarbital can be decreased when used in combination with Demecarium.Approved
DemeclocyclineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Demeclocycline.Approved
DemegestoneThe therapeutic efficacy of Demegestone can be decreased when used in combination with Phenobarbital.Approved
DeramciclaneThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Deramciclane.Investigational
DesfluranePhenobarbital may increase the hypotensive activities of Desflurane.Approved
DesipramineThe metabolism of Desipramine can be increased when combined with Phenobarbital.Approved, Investigational
DesloratadineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Desloratadine.Approved, Investigational
DesmethylsertralineThe serum concentration of Phenobarbital can be increased when it is combined with Desmethylsertraline.Experimental
DesogestrelThe therapeutic efficacy of Desogestrel can be decreased when used in combination with Phenobarbital.Approved
DesonideThe metabolism of Desonide can be increased when combined with Phenobarbital.Approved, Investigational
Desoxycorticosterone acetateThe metabolism of Desoxycorticosterone acetate can be increased when combined with Phenobarbital.Approved
Desoxycorticosterone PivalateThe metabolism of Desoxycorticosterone Pivalate can be increased when combined with Phenobarbital.Experimental, Vet Approved
DesvenlafaxineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Desvenlafaxine.Approved, Investigational
DetomidineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Detomidine.Vet Approved
DeutetrabenazineThe risk or severity of sedation and somnolence can be increased when Phenobarbital is combined with Deutetrabenazine.Approved, Investigational
DexamethasoneThe serum concentration of Dexamethasone can be decreased when it is combined with Phenobarbital.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe metabolism of Dexamethasone isonicotinate can be increased when combined with Phenobarbital.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Dexbrompheniramine.Approved
Dexchlorpheniramine maleateThe metabolism of Dexchlorpheniramine maleate can be increased when combined with Phenobarbital.Approved
DexetimideThe risk or severity of adverse effects can be increased when Dexetimide is combined with Phenobarbital.Withdrawn
DexfenfluramineThe metabolism of Dexfenfluramine can be increased when combined with Phenobarbital.Approved, Illicit, Investigational, Withdrawn
DexlansoprazoleThe metabolism of Dexlansoprazole can be increased when combined with Phenobarbital.Approved, Investigational
DexmedetomidinePhenobarbital may increase the hypotensive activities of Dexmedetomidine.Approved, Vet Approved
DexmethylphenidateThe serum concentration of Phenobarbital can be increased when it is combined with Dexmethylphenidate.Approved, Investigational
DexniguldipineThe metabolism of Dexniguldipine can be increased when combined with Phenobarbital.Experimental
DexrabeprazoleThe metabolism of Dexrabeprazole can be increased when combined with Phenobarbital.Experimental
DextofisopamThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Dextofisopam.Investigational
DextroamphetamineThe serum concentration of Phenobarbital can be decreased when it is combined with Dextroamphetamine.Approved, Illicit
DextromethorphanThe metabolism of Dextromethorphan can be increased when combined with Phenobarbital.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe metabolism of Dextropropoxyphene can be increased when combined with Phenobarbital.Approved, Illicit, Investigational, Withdrawn
DexverapamilThe metabolism of Dexverapamil can be increased when combined with Phenobarbital.Experimental
DezocineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Dezocine.Approved, Investigational
DiazepamThe metabolism of Diazepam can be increased when combined with Phenobarbital.Approved, Illicit, Investigational, Vet Approved
DibekacinThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Dibekacin.Experimental
DibenzepinThe metabolism of Dibenzepin can be increased when combined with Phenobarbital.Experimental
DichloralphenazoneThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Dichloralphenazone.Approved, Illicit
DichlorvosThe therapeutic efficacy of Phenobarbital can be decreased when used in combination with Dichlorvos.Vet Approved
DiclofenamidePhenobarbital may increase the hypotensive activities of Diclofenamide.Approved, Investigational
DicoumarolThe metabolism of Dicoumarol can be increased when combined with Phenobarbital.Approved
DicyclomineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Phenobarbital.Approved
DienogestThe serum concentration of Dienogest can be decreased when it is combined with Phenobarbital.Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Diethyl ether.Experimental
DiethylpropionThe serum concentration of Phenobarbital can be decreased when it is combined with Diethylpropion.Approved, Illicit
DiethylstilbestrolThe therapeutic efficacy of Diethylstilbestrol can be decreased when used in combination with Phenobarbital.Approved, Investigational
DifemerineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Difemerine.Experimental
DifenoxinThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Difenoxin.Approved, Illicit
DifluocortoloneThe metabolism of Difluocortolone can be increased when combined with Phenobarbital.Approved, Investigational, Withdrawn
DifluprednateThe metabolism of Difluprednate can be increased when combined with Phenobarbital.Approved
DigitoxinThe metabolism of Digitoxin can be increased when combined with Phenobarbital.Approved, Investigational
DigoxinThe metabolism of Digoxin can be increased when combined with Phenobarbital.Approved
DihexyverineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Dihexyverine.Experimental
DihydralazineThe metabolism of Dihydralazine can be increased when combined with Phenobarbital.Approved, Investigational
Dihydro-alpha-ergocryptineThe metabolism of Dihydro-alpha-ergocryptine can be increased when combined with Phenobarbital.Approved
DihydrocodeineThe metabolism of Dihydrocodeine can be increased when combined with Phenobarbital.Approved, Illicit
DihydroergocornineThe metabolism of Dihydroergocornine can be increased when combined with Phenobarbital.Approved
DihydroergocristineThe metabolism of Dihydroergocristine can be increased when combined with Phenobarbital.Approved, Experimental
DihydroergocryptineThe metabolism of Dihydroergocryptine can be increased when combined with Phenobarbital.Experimental
DihydroergotamineThe metabolism of Dihydroergotamine can be increased when combined with Phenobarbital.Approved, Investigational
DihydroetorphineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Dihydromorphine.Experimental, Illicit
DihydrostreptomycinThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Dihydrostreptomycin.Investigational, Vet Approved
DiltiazemPhenobarbital may increase the hypotensive activities of Diltiazem.Approved, Investigational
DimenhydrinateThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Dimenhydrinate.Approved
DimetacrineThe metabolism of Dimetacrine can be increased when combined with Phenobarbital.Approved, Withdrawn
DimethyltryptamineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Dimethyltryptamine.Experimental, Illicit
DimetindeneThe risk or severity of adverse effects can be increased when Dimetindene is combined with Phenobarbital.Approved, Investigational
DinoprostoneThe metabolism of Dinoprostone can be increased when combined with Phenobarbital.Approved
DinutuximabPhenobarbital may increase the hypotensive activities of Dinutuximab.Approved, Investigational
DiphemanilThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Diphemanil.Experimental
Diphemanil MethylsulfateThe risk or severity of adverse effects can be increased when Diphemanil Methylsulfate is combined with Phenobarbital.Approved, Vet Approved, Withdrawn
DiphenadioneThe metabolism of Diphenadione can be increased when combined with Phenobarbital.Experimental
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Phenobarbital.Approved, Investigational
DiphenidolThe risk or severity of adverse effects can be increased when Diphenidol is combined with Phenobarbital.Approved, Investigational, Withdrawn
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Phenobarbital.Approved, Illicit
DipyridamolePhenobarbital may increase the hypotensive activities of Dipyridamole.Approved
DisopyramideThe serum concentration of Disopyramide can be decreased when it is combined with Phenobarbital.Approved
DistigmineThe therapeutic efficacy of Phenobarbital can be decreased when used in combination with Distigmine.Experimental
DisulfiramThe metabolism of Disulfiram can be increased when combined with Phenobarbital.Approved
DixyrazineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Dixyrazine.Experimental
DocetaxelThe metabolism of Docetaxel can be increased when combined with Phenobarbital.Approved, Investigational
DofequidarThe serum concentration of Phenobarbital can be increased when it is combined with Dofequidar.Experimental, Investigational
DofetilideThe metabolism of Dofetilide can be increased when combined with Phenobarbital.Approved, Investigational
DolasetronThe metabolism of Dolasetron can be increased when combined with Phenobarbital.Approved, Investigational
DolutegravirThe serum concentration of Dolutegravir can be decreased when it is combined with Phenobarbital.Approved
Domoic AcidThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Domoic Acid.Experimental
DomperidoneThe metabolism of Domperidone can be increased when combined with Phenobarbital.Approved, Investigational, Vet Approved
DonepezilThe therapeutic efficacy of Phenobarbital can be decreased when used in combination with Donepezil.Approved
DopamineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Dopamine.Approved
DoramectinThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Doramectin.Vet Approved
DorzolamideThe metabolism of Dorzolamide can be increased when combined with Phenobarbital.Approved
DosulepinThe metabolism of Dosulepin can be increased when combined with Phenobarbital.Approved
DotarizineThe metabolism of Dotarizine can be increased when combined with Phenobarbital.Investigational
DovitinibThe serum concentration of Phenobarbital can be increased when it is combined with Dovitinib.Investigational
DoxacuriumThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Doxacurium.Approved
DoxazosinPhenobarbital may increase the hypotensive activities of Doxazosin.Approved
DoxefazepamThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Doxefazepam.Experimental
DoxepinThe metabolism of Doxepin can be increased when combined with Phenobarbital.Approved, Investigational
DoxofyllineThe serum concentration of Doxofylline can be decreased when it is combined with Phenobarbital.Approved, Investigational
DoxorubicinThe serum concentration of Doxorubicin can be decreased when it is combined with Phenobarbital.Approved, Investigational
DoxycyclineThe serum concentration of Doxycycline can be decreased when it is combined with Phenobarbital.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Phenobarbital.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Phenobarbital is combined with DPDPE.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Phenobarbital.Approved, Illicit
DronedaroneThe serum concentration of Dronedarone can be decreased when it is combined with Phenobarbital.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Phenobarbital.Approved, Vet Approved
DrospirenoneThe therapeutic efficacy of Drospirenone can be decreased when used in combination with Phenobarbital.Approved
DrotebanolThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Drotebanol.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Duloxetine.Approved
DutasterideThe metabolism of Dutasteride can be increased when combined with Phenobarbital.Approved, Investigational
DyclonineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Dyclonine.Approved
DydrogesteroneThe metabolism of Dydrogesterone can be increased when combined with Phenobarbital.Approved, Investigational, Withdrawn
EchothiophateThe therapeutic efficacy of Phenobarbital can be decreased when used in combination with Echothiophate.Approved
EconazoleThe serum concentration of Phenobarbital can be increased when it is combined with Econazole.Approved
EcopipamThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Ecopipam.Investigational
EdivoxetineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Edivoxetine.Investigational
EdrophoniumThe therapeutic efficacy of Phenobarbital can be decreased when used in combination with Edrophonium.Approved
EfavirenzThe metabolism of Efavirenz can be increased when combined with Phenobarbital.Approved, Investigational
EfonidipinePhenobarbital may increase the hypotensive activities of Efonidipine.Approved, Investigational
ElacridarThe serum concentration of Phenobarbital can be increased when it is combined with Elacridar.Investigational
ElagolixThe serum concentration of Elagolix can be decreased when it is combined with Phenobarbital.Approved, Investigational
ElbasvirThe metabolism of Elbasvir can be increased when combined with Phenobarbital.Approved
EletriptanThe metabolism of Eletriptan can be increased when combined with Phenobarbital.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be decreased when it is combined with Phenobarbital.Approved
EltanoloneThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Eltanolone.Investigational
EltoprazineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Eltoprazine.Investigational
EltrombopagThe serum concentration of Eltrombopag can be decreased when it is combined with Phenobarbital.Approved
EluxadolineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Eluxadoline.Approved, Investigational
EmeproniumThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Emepronium.Experimental
EmopamilThe metabolism of Emopamil can be increased when combined with Phenobarbital.Experimental
EmpagliflozinPhenobarbital may increase the hypotensive activities of Empagliflozin.Approved
EmylcamateThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Emylcamate.Experimental
EnalaprilPhenobarbital may increase the hypotensive activities of Enalapril.Approved, Vet Approved
EnalaprilatPhenobarbital may increase the hypotensive activities of Enalaprilat.Approved
EnasidenibThe serum concentration of Enasidenib can be decreased when it is combined with Phenobarbital.Approved, Investigational
EncorafenibThe metabolism of Encorafenib can be increased when combined with Phenobarbital.Approved, Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Enflurane.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Entacapone.Approved, Investigational
EntecavirThe serum concentration of Entecavir can be decreased when it is combined with Phenobarbital.Approved, Investigational
EnzalutamideThe serum concentration of Enzalutamide can be decreased when it is combined with Phenobarbital.Approved
EpanololThe serum concentration of Epanolol can be decreased when it is combined with Phenobarbital.Experimental
EperisoneThe metabolism of Eperisone can be increased when combined with Phenobarbital.Approved, Investigational
EpinastineThe metabolism of Epinastine can be increased when combined with Phenobarbital.Approved, Investigational
EpitizideThe risk or severity of hypotension and orthostatic hypotension can be increased when Phenobarbital is combined with Epitizide.Experimental
EplerenonePhenobarbital may increase the hypotensive activities of Eplerenone.Approved
EplivanserinThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Eplivanserin.Investigational
EpoprostenolPhenobarbital may increase the hypotensive activities of Epoprostenol.Approved
EprosartanPhenobarbital may increase the hypotensive activities of Eprosartan.Approved
EquileninThe metabolism of Equilenin can be increased when combined with Phenobarbital.Experimental
EquilinThe metabolism of Equilin can be increased when combined with Phenobarbital.Approved
ErgocalciferolThe metabolism of Ergocalciferol can be increased when combined with Phenobarbital.Approved, Nutraceutical
Ergoloid mesylateThe metabolism of Ergoloid mesylate can be increased when combined with Phenobarbital.Approved
ErgonovineThe metabolism of Ergonovine can be increased when combined with Phenobarbital.Approved
ErgotamineThe metabolism of Ergotamine can be increased when combined with Phenobarbital.Approved
ErlotinibThe serum concentration of Erlotinib can be decreased when it is combined with Phenobarbital.Approved, Investigational
ErythromycinThe metabolism of Erythromycin can be increased when combined with Phenobarbital.Approved, Investigational, Vet Approved
EsatenololThe serum concentration of Esatenolol can be decreased when it is combined with Phenobarbital.Experimental
EscitalopramThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Eslicarbazepine acetate can be decreased when it is combined with Phenobarbital.Approved
EsmirtazapineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Esmirtazapine.Investigational
EsmololPhenobarbital may increase the hypotensive activities of Esmolol.Approved
EsomeprazoleThe metabolism of Esomeprazole can be increased when combined with Phenobarbital.Approved, Investigational
EsreboxetineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Esreboxetine.Investigational
EstazolamThe metabolism of Estazolam can be increased when combined with Phenobarbital.Approved, Illicit
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Phenobarbital.Approved, Investigational, Vet Approved
Estradiol acetateThe serum concentration of Estradiol acetate can be decreased when it is combined with Phenobarbital.Approved, Investigational, Vet Approved
Estradiol benzoateThe serum concentration of Estradiol benzoate can be decreased when it is combined with Phenobarbital.Approved, Investigational, Vet Approved
Estradiol cypionateThe serum concentration of Estradiol cypionate can be decreased when it is combined with Phenobarbital.Approved, Investigational, Vet Approved
Estradiol dienanthateThe serum concentration of Estradiol dienanthate can be decreased when it is combined with Phenobarbital.Approved, Investigational, Vet Approved
Estradiol valerateThe serum concentration of Estradiol valerate can be decreased when it is combined with Phenobarbital.Approved, Investigational, Vet Approved
EstramustineThe metabolism of Estramustine can be increased when combined with Phenobarbital.Approved, Investigational
Estrogens, esterifiedThe metabolism of Estrogens, esterified can be increased when combined with Phenobarbital.Approved
EstroneThe metabolism of Estrone can be increased when combined with Phenobarbital.Approved
Estrone sulfateThe metabolism of Estrone sulfate can be increased when combined with Phenobarbital.Approved
EszopicloneThe metabolism of Eszopiclone can be increased when combined with Phenobarbital.Approved, Investigational
Etacrynic acidPhenobarbital may increase the hypotensive activities of Etacrynic acid.Approved, Investigational
EtamiphyllineThe serum concentration of Etamiphylline can be decreased when it is combined with Phenobarbital.Experimental
EtanautineThe risk or severity of adverse effects can be increased when Etanautine is combined with Phenobarbital.Experimental
EthadioneThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Ethadione.Experimental
EthanolPhenobarbital may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Ethchlorvynol.Approved, Illicit, Withdrawn
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Phenobarbital.Approved
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Phenobarbital.Approved
EthosuximideThe metabolism of Ethosuximide can be increased when combined with Phenobarbital.Approved
EthotoinThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Ethotoin.Approved
Ethyl biscoumacetateThe metabolism of Ethyl biscoumacetate can be increased when combined with Phenobarbital.Withdrawn
Ethyl carbamateThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Ethyl chloride.Approved, Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe metabolism of Ethylmorphine can be increased when combined with Phenobarbital.Approved, Illicit
EthynodiolThe metabolism of Ethynodiol can be increased when combined with Phenobarbital.Experimental
Ethynodiol diacetateThe therapeutic efficacy of Ethynodiol diacetate can be decreased when used in combination with Phenobarbital.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Etifoxine.Investigational, Withdrawn
EtiracetamThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Etiracetam.Investigational
EtizolamThe metabolism of Etizolam can be increased when combined with Phenobarbital.Approved
EtomidateThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Etomidate.Approved
EtonogestrelThe therapeutic efficacy of Etonogestrel can be decreased when used in combination with Phenobarbital.Approved, Investigational
EtoperidoneThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Etoperidone.Withdrawn
EtoricoxibThe metabolism of Etoricoxib can be increased when combined with Phenobarbital.Approved, Investigational
EtorphineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Etorphine.Illicit, Vet Approved
EtravirineThe serum concentration of Etravirine can be decreased when it is combined with Phenobarbital.Approved
EtybenzatropineThe risk or severity of adverse effects can be increased when Etybenzatropine is combined with Phenobarbital.Experimental
EverolimusThe serum concentration of Everolimus can be decreased when it is combined with Phenobarbital.Approved
ExemestaneThe serum concentration of Exemestane can be decreased when it is combined with Phenobarbital.Approved, Investigational
EzetimibeThe serum concentration of Ezetimibe can be decreased when it is combined with Phenobarbital.Approved
EzogabineThe serum concentration of Ezogabine can be decreased when it is combined with Phenobarbital.Approved, Investigational
FabomotizoleThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Fabomotizole.Experimental
FamciclovirThe metabolism of Famciclovir can be increased when combined with Phenobarbital.Approved, Investigational
Fazadinium bromideThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Fazadinium bromide.Experimental
FebarbamateThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Febarbamate.Experimental
FelbamateThe serum concentration of Felbamate can be decreased when it is combined with Phenobarbital.Approved
FelodipinePhenobarbital may increase the hypotensive activities of Felodipine.Approved, Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Fencamfamine.Approved, Illicit, Withdrawn
FendilineThe metabolism of Fendiline can be increased when combined with Phenobarbital.Withdrawn
FenethyllineThe serum concentration of Fenethylline can be decreased when it is combined with Phenobarbital.Approved
FenfluramineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Fenfluramine.Approved, Illicit, Investigational, Withdrawn
FenofibrateThe serum concentration of Fenofibrate can be decreased when it is combined with Phenobarbital.Approved
FenoldopamPhenobarbital may increase the hypotensive activities of Fenoldopam.Approved
FenpiveriniumThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Fenpiverinium.Experimental
FentanylThe serum concentration of Fentanyl can be decreased when it is combined with Phenobarbital.Approved, Illicit, Investigational, Vet Approved
FenthionThe therapeutic efficacy of Phenobarbital can be decreased when used in combination with Fenthion.Vet Approved
FenyramidolThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Fenyramidol.Experimental
FesoterodineThe metabolism of Fesoterodine can be increased when combined with Phenobarbital.Approved
FexofenadineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Fexofenadine.Approved, Investigational
FimasartanPhenobarbital may increase the hypotensive activities of Fimasartan.Approved, Investigational
FinasterideThe metabolism of Finasteride can be increased when combined with Phenobarbital.Approved
FingolimodThe metabolism of Fingolimod can be increased when combined with Phenobarbital.Approved, Investigational
Fish oilThe metabolism of Fish oil can be increased when combined with Phenobarbital.Approved, Nutraceutical
FlavoxateThe risk or severity of adverse effects can be increased when Flavoxate is combined with Phenobarbital.Approved
FlibanserinThe serum concentration of Flibanserin can be decreased when it is combined with Phenobarbital.Approved, Investigational
FluanisoneThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Fluanisone.Experimental
FluconazoleThe metabolism of Phenobarbital can be decreased when combined with Fluconazole.Approved, Investigational
FludiazepamThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Fludiazepam.Approved, Illicit
FludrocortisoneThe metabolism of Fludrocortisone can be increased when combined with Phenobarbital.Approved, Investigational
FluindioneThe metabolism of Fluindione can be increased when combined with Phenobarbital.Approved, Investigational
FlumethasoneThe metabolism of Flumethasone can be increased when combined with Phenobarbital.Approved, Vet Approved
FlunarizineThe metabolism of Flunarizine can be increased when combined with Phenobarbital.Approved
FlunisolideThe metabolism of Flunisolide can be increased when combined with Phenobarbital.Approved, Investigational
FlunitrazepamThe metabolism of Flunitrazepam can be increased when combined with Phenobarbital.Approved, Illicit
Fluocinolone AcetonideThe metabolism of Fluocinolone Acetonide can be increased when combined with Phenobarbital.Approved, Investigational, Vet Approved
FluocinonideThe metabolism of Fluocinonide can be increased when combined with Phenobarbital.Approved, Investigational
FluocortoloneThe metabolism of Fluocortolone can be increased when combined with Phenobarbital.Approved, Withdrawn
FluorometholoneThe metabolism of Fluorometholone can be increased when combined with Phenobarbital.Approved, Investigational
FluorouracilThe metabolism of Fluorouracil can be increased when combined with Phenobarbital.Approved
FluoxetineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Phenobarbital.Approved, Investigational, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Phenobarbital.Approved
FluprednideneThe metabolism of Fluprednidene can be increased when combined with Phenobarbital.Approved, Withdrawn
FluprednisoloneThe metabolism of Fluprednisolone can be increased when combined with Phenobarbital.Approved
FlurandrenolideThe metabolism of Flurandrenolide can be increased when combined with Phenobarbital.Approved
FlurazepamThe metabolism of Flurazepam can be increased when combined with Phenobarbital.Approved, Illicit, Investigational
FlurbiprofenThe serum concentration of Flurbiprofen can be decreased when it is combined with Phenobarbital.Approved, Investigational
FluspirileneThe metabolism of Fluspirilene can be increased when combined with Phenobarbital.Approved, Investigational
FlutamideThe metabolism of Flutamide can be increased when combined with Phenobarbital.Approved, Investigational
FluticasoneThe metabolism of Fluticasone can be increased when combined with Phenobarbital.Approved, Experimental, Investigational
Fluticasone furoateThe metabolism of Fluticasone furoate can be increased when combined with Phenobarbital.Approved
Fluticasone propionateThe metabolism of Fluticasone propionate can be increased when combined with Phenobarbital.Approved
FluvastatinThe serum concentration of Fluvastatin can be decreased when it is combined with Phenobarbital.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Fluvoxamine.Approved, Investigational
Folic AcidThe serum concentration of Phenobarbital can be decreased when it is combined with Folic Acid.Approved, Nutraceutical, Vet Approved
FosamprenavirThe serum concentration of Phenobarbital can be increased when it is combined with Fosamprenavir.Approved
FosaprepitantThe metabolism of Fosaprepitant can be increased when combined with Phenobarbital.Approved
FosinoprilPhenobarbital may increase the hypotensive activities of Fosinopril.Approved
FosnetupitantThe metabolism of Fosnetupitant can be increased when combined with Phenobarbital.Approved
FosphenytoinFosphenytoin may increase the central nervous system depressant (CNS depressant) activities of Phenobarbital.Approved, Investigational
FospropofolThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Fospropofol.Approved, Illicit, Investigational
FostamatinibThe metabolism of Fostamatinib can be increased when combined with Phenobarbital.Approved, Investigational
FramycetinThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Framycetin.Approved
FrovatriptanThe metabolism of Frovatriptan can be increased when combined with Phenobarbital.Approved, Investigational
FulvestrantThe serum concentration of Fulvestrant can be decreased when it is combined with Phenobarbital.Approved, Investigational
FurafyllineThe serum concentration of Furafylline can be decreased when it is combined with Phenobarbital.Experimental
FurazolidoneThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Furazolidone.Approved, Investigational, Vet Approved
FurosemideThe serum concentration of Furosemide can be decreased when it is combined with Phenobarbital.Approved, Vet Approved
GabapentinThe metabolism of Gabapentin can be increased when combined with Phenobarbital.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Gabapentin Enacarbil.Approved, Investigational
GaboxadolThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Gaboxadol.Investigational
GalantamineThe therapeutic efficacy of Phenobarbital can be decreased when used in combination with Galantamine.Approved
GallamineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Gallamine.Experimental
Gallamine TriethiodideThe therapeutic efficacy of Phenobarbital can be decreased when used in combination with Gallamine Triethiodide.Approved
GallopamilThe metabolism of Gallopamil can be increased when combined with Phenobarbital.Investigational
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Gamma Hydroxybutyric Acid.Approved, Illicit, Investigational
GanciclovirThe serum concentration of Ganciclovir can be decreased when it is combined with Phenobarbital.Approved, Investigational
Gantacurium ChlorideThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Gantacurium Chloride.Investigational
GavestinelThe serum concentration of Gavestinel can be decreased when it is combined with Phenobarbital.Investigational
GedocarnilThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Gedocarnil.Experimental
GefitinibThe serum concentration of Gefitinib can be decreased when it is combined with Phenobarbital.Approved, Investigational
GemfibrozilThe serum concentration of Gemfibrozil can be decreased when it is combined with Phenobarbital.Approved
GeneticinThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Geneticin.Experimental
GenisteinThe metabolism of Genistein can be increased when combined with Phenobarbital.Investigational
GentamicinThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Gentamicin.Approved, Vet Approved
GENTAMICIN C1AThe risk or severity of adverse effects can be increased when Phenobarbital is combined with GENTAMICIN C1A.Experimental
GepefrineThe serum concentration of Phenobarbital can be decreased when it is combined with Gepefrine.Experimental
GepironeThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Gepirone.Investigational
GestodeneThe therapeutic efficacy of Gestodene can be decreased when used in combination with Phenobarbital.Approved, Investigational
GestrinoneThe therapeutic efficacy of Gestrinone can be decreased when used in combination with Phenobarbital.Approved
Ginkgo bilobaThe therapeutic efficacy of Phenobarbital can be decreased when used in combination with Ginkgo biloba.Approved, Investigational, Nutraceutical
GlecaprevirThe serum concentration of Phenobarbital can be increased when it is combined with Glecaprevir.Approved, Investigational
GlibornurideThe metabolism of Glibornuride can be increased when combined with Phenobarbital.Investigational, Withdrawn
GliclazideThe metabolism of Gliclazide can be increased when combined with Phenobarbital.Approved
GlimepirideThe metabolism of Glimepiride can be increased when combined with Phenobarbital.Approved
GlipizideThe serum concentration of Glipizide can be decreased when it is combined with Phenobarbital.Approved, Investigational
GliquidoneThe metabolism of Gliquidone can be increased when combined with Phenobarbital.Approved, Investigational
GlisoxepideThe metabolism of Glisoxepide can be increased when combined with Phenobarbital.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Glutethimide.Approved, Illicit
GlyburideThe metabolism of Glyburide can be increased when combined with Phenobarbital.Approved
GlycerinThe serum concentration of Phenobarbital can be increased when it is combined with Glycerin.Approved, Investigational
GlycopyrroniumThe risk or severity of adverse effects can be increased when Glycopyrronium is combined with Phenobarbital.Approved, Investigational, Vet Approved
Gramicidin DThe serum concentration of Phenobarbital can be increased when it is combined with Gramicidin D.Approved
GranisetronThe metabolism of Granisetron can be increased when combined with Phenobarbital.Approved, Investigational
GrazoprevirThe metabolism of Grazoprevir can be increased when combined with Phenobarbital.Approved
GrepafloxacinThe metabolism of Grepafloxacin can be increased when combined with Phenobarbital.Approved, Investigational, Withdrawn
GriseofulvinThe serum concentration of Griseofulvin can be decreased when it is combined with Phenobarbital.Approved, Investigational, Vet Approved
GuanabenzThe metabolism of Guanabenz can be increased when combined with Phenobarbital.Approved, Investigational
GuanfacineThe serum concentration of Guanfacine can be decreased when it is combined with Phenobarbital.Approved, Investigational
GuanineThe serum concentration of Guanine can be decreased when it is combined with Phenobarbital.Experimental
HalazepamThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Halazepam.Approved, Illicit, Withdrawn
HalcinonideThe metabolism of Halcinonide can be increased when combined with Phenobarbital.Approved, Investigational, Withdrawn
HalofantrineThe metabolism of Halofantrine can be increased when combined with Phenobarbital.Approved
HaloperidolThe metabolism of Haloperidol can be increased when combined with Phenobarbital.Approved
HalothanePhenobarbital may increase the hypotensive activities of Halothane.Approved, Vet Approved
HarmalineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Harmaline.Experimental
HE3286The metabolism of HE3286 can be increased when combined with Phenobarbital.Investigational
HeptabarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Heptabarbital.Approved
HeroinThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Heroin.Approved, Illicit, Investigational
HexafluroniumThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Hexafluronium.Approved
HexamethoniumThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Hexamethonium.Experimental
HexapropymateThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Hexapropymate.Experimental
HexobarbitalThe metabolism of Hexobarbital can be increased when combined with Phenobarbital.Approved
HexocycliumThe risk or severity of adverse effects can be increased when Hexocyclium is combined with Phenobarbital.Approved
HistamineThe metabolism of Histamine can be increased when combined with Phenobarbital.Approved, Investigational
HM-30181The serum concentration of Phenobarbital can be increased when it is combined with HM-30181.Experimental
HomatropineThe risk or severity of adverse effects can be increased when Homatropine is combined with Phenobarbital.Approved
Homatropine MethylbromideThe risk or severity of adverse effects can be increased when Homatropine Methylbromide is combined with Phenobarbital.Approved
Huperzine AThe therapeutic efficacy of Phenobarbital can be decreased when used in combination with Huperzine A.Approved, Investigational
HycanthoneThe serum concentration of Phenobarbital can be increased when it is combined with Hycanthone.Approved, Investigational
HydracarbazineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Hydracarbazine.Experimental
HydralazinePhenobarbital may increase the hypotensive activities of Hydralazine.Approved
HydrochlorothiazideThe risk or severity of hypotension and orthostatic hypotension can be increased when Phenobarbital is combined with Hydrochlorothiazide.Approved, Vet Approved
HydrocodonePhenobarbital may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydrocortisoneThe serum concentration of Hydrocortisone can be decreased when it is combined with Phenobarbital.Approved, Vet Approved
Hydrocortisone aceponateThe metabolism of Hydrocortisone aceponate can be increased when combined with Phenobarbital.Experimental, Vet Approved
Hydrocortisone acetateThe metabolism of Hydrocortisone acetate can be increased when combined with Phenobarbital.Approved, Vet Approved
Hydrocortisone butyrateThe metabolism of Hydrocortisone butyrate can be increased when combined with Phenobarbital.Approved, Vet Approved
Hydrocortisone cypionateThe metabolism of Hydrocortisone cypionate can be increased when combined with Phenobarbital.Approved, Vet Approved
Hydrocortisone phosphateThe metabolism of Hydrocortisone phosphate can be increased when combined with Phenobarbital.Approved, Vet Approved
Hydrocortisone probutateThe metabolism of Hydrocortisone probutate can be increased when combined with Phenobarbital.Approved, Vet Approved
Hydrocortisone succinateThe metabolism of Hydrocortisone succinate can be increased when combined with Phenobarbital.Approved
Hydrocortisone valerateThe metabolism of Hydrocortisone valerate can be increased when combined with Phenobarbital.Approved, Vet Approved
HydroflumethiazideThe risk or severity of hypotension and orthostatic hypotension can be increased when Phenobarbital is combined with Hydroflumethiazide.Approved, Investigational
HydromorphoneThe metabolism of Hydromorphone can be increased when combined with Phenobarbital.Approved, Illicit
HydroxyamphetamineThe serum concentration of Phenobarbital can be decreased when it is combined with Hydroxyamphetamine.Approved
HydroxychloroquineThe serum concentration of Phenobarbital can be increased when it is combined with Hydroxychloroquine.Approved
HydroxyprogesteroneThe metabolism of Hydroxyprogesterone can be increased when combined with Phenobarbital.Experimental
Hydroxyprogesterone caproateThe therapeutic efficacy of Hydroxyprogesterone caproate can be decreased when used in combination with Phenobarbital.Approved, Investigational
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Phenobarbital.Approved
Hygromycin BThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Hygromycin B.Vet Approved
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Phenobarbital.Approved
HypericinThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Hypericin.Investigational
HypoxanthineThe serum concentration of Hypoxanthine can be decreased when it is combined with Phenobarbital.Experimental
IbrutinibThe serum concentration of Ibrutinib can be decreased when it is combined with Phenobarbital.Approved
IbuprofenThe serum concentration of Ibuprofen can be decreased when it is combined with Phenobarbital.Approved
IcotinibThe metabolism of Icotinib can be increased when combined with Phenobarbital.Approved, Investigational
IdalopirdineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Idalopirdine.Investigational
IdelalisibThe serum concentration of Idelalisib can be decreased when it is combined with Phenobarbital.Approved
IfenprodilThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Ifenprodil.Approved, Investigational, Withdrawn
IferanserinThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Iferanserin.Investigational
IfosfamideThe serum concentration of the active metabolites of Ifosfamide can be increased when Ifosfamide is used in combination with Phenobarbital.Approved
IloperidoneThe metabolism of Iloperidone can be increased when combined with Phenobarbital.Approved
IloprostPhenobarbital may increase the hypotensive activities of Iloprost.Approved, Investigational
ImagabalinThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Imagabalin.Investigational
ImatinibThe serum concentration of Imatinib can be decreased when it is combined with Phenobarbital.Approved
ImidafenacinThe metabolism of Imidafenacin can be increased when combined with Phenobarbital.Approved, Investigational
ImidaprilPhenobarbital may increase the hypotensive activities of Imidapril.Investigational
ImipramineThe metabolism of Imipramine can be increased when combined with Phenobarbital.Approved
Imipramine oxideThe metabolism of Imipramine oxide can be increased when combined with Phenobarbital.Experimental
ImiquimodThe metabolism of Imiquimod can be increased when combined with Phenobarbital.Approved, Investigational
IndacaterolThe serum concentration of Indacaterol can be decreased when it is combined with Phenobarbital.Approved
IndalpineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Indalpine.Investigational, Withdrawn
IndapamideThe risk or severity of hypotension and orthostatic hypotension can be increased when Phenobarbital is combined with Indapamide.Approved
IndenololThe serum concentration of Indenolol can be decreased when it is combined with Phenobarbital.Withdrawn
IndinavirThe serum concentration of Phenobarbital can be increased when it is combined with Indinavir.Approved
IndiplonThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Indiplon.Investigational
IndomethacinThe serum concentration of Indomethacin can be decreased when it is combined with Phenobarbital.Approved, Investigational
IndoraminPhenobarbital may increase the hypotensive activities of Indoramin.Withdrawn
Iofetamine I-123The serum concentration of Phenobarbital can be decreased when it is combined with Iofetamine I-123.Approved
IpecacThe metabolism of Ipecac can be increased when combined with Phenobarbital.Approved, Withdrawn
IpidacrineThe therapeutic efficacy of Phenobarbital can be decreased when used in combination with Ipidacrine.Experimental
IpratropiumThe metabolism of Ipratropium can be increased when combined with Phenobarbital.Approved
IprazochromeThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Iprazochrome.Experimental
IprindoleThe metabolism of Iprindole can be increased when combined with Phenobarbital.Experimental
IproclozideThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Iproclozide.Withdrawn
IproniazidThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Iproniazid.Withdrawn
IrbesartanPhenobarbital may increase the hypotensive activities of Irbesartan.Approved, Investigational
IrinotecanThe serum concentration of Irinotecan can be decreased when it is combined with Phenobarbital.Approved, Investigational
IsavuconazoleThe serum concentration of Isavuconazole can be decreased when it is combined with Phenobarbital.Approved, Investigational
IsavuconazoniumThe serum concentration of the active metabolites of Isavuconazonium can be reduced when Isavuconazonium is used in combination with Phenobarbital resulting in a loss in efficacy.Approved, Investigational
IsepamicinThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Isepamicin.Experimental
IsocarboxazidPhenobarbital may increase the hypotensive activities of Isocarboxazid.Approved
IsofluranePhenobarbital may increase the hypotensive activities of Isoflurane.Approved, Vet Approved
IsoflurophateThe therapeutic efficacy of Phenobarbital can be decreased when used in combination with Isoflurophate.Approved, Investigational, Withdrawn
IsopropamideThe risk or severity of adverse effects can be increased when Isopropamide is combined with Phenobarbital.Approved, Vet Approved
Isosorbide DinitratePhenobarbital may increase the hypotensive activities of Isosorbide Dinitrate.Approved, Investigational
Isosorbide MononitratePhenobarbital may increase the hypotensive activities of Isosorbide Mononitrate.Approved
IsoxsuprinePhenobarbital may increase the hypotensive activities of Isoxsuprine.Approved, Withdrawn
IsradipinePhenobarbital may increase the hypotensive activities of Isradipine.Approved, Investigational
ItoprideThe therapeutic efficacy of Phenobarbital can be decreased when used in combination with Itopride.Investigational
ItraconazoleThe serum concentration of Itraconazole can be decreased when it is combined with Phenobarbital.Approved, Investigational
IvabradineThe serum concentration of Ivabradine can be decreased when it is combined with Phenobarbital.Approved
IvacaftorThe serum concentration of Ivacaftor can be decreased when it is combined with Phenobarbital.Approved
IvermectinThe metabolism of Ivermectin can be increased when combined with Phenobarbital.Approved, Investigational, Vet Approved
IvosidenibThe metabolism of Ivosidenib can be increased when combined with Phenobarbital.Approved, Investigational
IxabepiloneThe serum concentration of Ixabepilone can be decreased when it is combined with Phenobarbital.Approved, Investigational
IxazomibThe serum concentration of Ixazomib can be decreased when it is combined with Phenobarbital.Approved, Investigational
KanamycinThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Kanamycin.Approved, Investigational, Vet Approved
KetamineThe metabolism of Ketamine can be increased when combined with Phenobarbital.Approved, Vet Approved
KetanserinThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Ketanserin.Investigational
KetazolamThe metabolism of Ketazolam can be increased when combined with Phenobarbital.Approved
KetobemidoneThe metabolism of Ketobemidone can be increased when combined with Phenobarbital.Approved, Investigational
KetoconazoleThe metabolism of Ketoconazole can be increased when combined with Phenobarbital.Approved, Investigational
KetoprofenThe serum concentration of Ketoprofen can be decreased when it is combined with Phenobarbital.Approved, Vet Approved
L-TryptophanThe risk or severity of adverse effects can be increased when Phenobarbital is combined with L-Tryptophan.Approved, Nutraceutical, Withdrawn
LabetalolPhenobarbital may increase the hypotensive activities of Labetalol.Approved
LacidipineThe serum concentration of Lacidipine can be decreased when it is combined with Phenobarbital.Approved, Investigational
LacosamideThe serum concentration of Lacosamide can be decreased when it is combined with Phenobarbital.Approved
LandiololThe serum concentration of Landiolol can be decreased when it is combined with Phenobarbital.Investigational
LanicemineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Lanicemine.Investigational
LaniquidarThe serum concentration of Phenobarbital can be increased when it is combined with Laniquidar.Investigational
LansoprazoleThe metabolism of Lansoprazole can be increased when combined with Phenobarbital.Approved, Investigational
LapatinibThe serum concentration of Lapatinib can be decreased when it is combined with Phenobarbital.Approved, Investigational
LaquinimodThe metabolism of Laquinimod can be increased when combined with Phenobarbital.Investigational
LasmiditanThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Lasmiditan.Investigational
LedipasvirThe serum concentration of Ledipasvir can be decreased when it is combined with Phenobarbital.Approved
LercanidipinePhenobarbital may increase the hypotensive activities of Lercanidipine.Approved, Investigational
LetermovirThe serum concentration of Letermovir can be decreased when it is combined with Phenobarbital.Approved, Investigational
LetrozoleThe metabolism of Letrozole can be increased when combined with Phenobarbital.Approved, Investigational
LeucovorinThe serum concentration of Phenobarbital can be decreased when it is combined with Leucovorin.Approved
LeuprolideThe metabolism of Leuprolide can be increased when combined with Phenobarbital.Approved, Investigational
LevetiracetamThe metabolism of Levetiracetam can be increased when combined with Phenobarbital.Approved, Investigational
LevobetaxololThe serum concentration of Levobetaxolol can be decreased when it is combined with Phenobarbital.Approved, Investigational
LevobunololPhenobarbital may increase the hypotensive activities of Levobunolol.Approved
LevobupivacainePhenobarbital may increase the hypotensive activities of Levobupivacaine.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Levocabastine.Approved, Investigational
LevocetirizineThe metabolism of Levocetirizine can be increased when combined with Phenobarbital.Approved
LevodopaPhenobarbital may increase the hypotensive activities of Levodopa.Approved
LevofloxacinThe serum concentration of Phenobarbital can be increased when it is combined with Levofloxacin.Approved, Investigational
LevoleucovorinThe serum concentration of Phenobarbital can be decreased when it is combined with Levoleucovorin.Approved, Investigational
Levomefolic acidThe serum concentration of Phenobarbital can be decreased when it is combined with Levomefolic acid.Approved, Investigational
Levomethadyl AcetateThe metabolism of Levomethadyl Acetate can be increased when combined with Phenobarbital.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Levomilnacipran.Approved, Investigational
LevonorgestrelThe therapeutic efficacy of Levonorgestrel can be decreased when used in combination with Phenobarbital.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Phenobarbital.Approved
LevosimendanPhenobarbital may increase the hypotensive activities of Levosimendan.Approved, Investigational
LevothyroxineThe serum concentration of Levothyroxine can be decreased when it is combined with Phenobarbital.Approved
LidocaineThe metabolism of Lidocaine can be increased when combined with Phenobarbital.Approved, Vet Approved
LidoflazineThe metabolism of Lidoflazine can be increased when combined with Phenobarbital.Experimental
LinagliptinThe serum concentration of Linagliptin can be decreased when it is combined with Phenobarbital.Approved
LincomycinThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Lincomycin.Approved, Vet Approved
LinezolidThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Linezolid.Approved, Investigational
LiothyronineThe metabolism of Liothyronine can be increased when combined with Phenobarbital.Approved, Vet Approved
LiotrixThe metabolism of Liotrix can be increased when combined with Phenobarbital.Approved
LisdexamfetamineThe serum concentration of Phenobarbital can be decreased when it is combined with Lisdexamfetamine.Approved, Investigational
LisinoprilPhenobarbital may increase the hypotensive activities of Lisinopril.Approved, Investigational
LisofyllineThe serum concentration of Lisofylline can be decreased when it is combined with Phenobarbital.Investigational
LisurideThe metabolism of Lisuride can be increased when combined with Phenobarbital.Approved, Investigational
Lithium carbonateThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Lithium carbonate.Approved
Lithium cationThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Lithium cation.Experimental
LobeglitazoneThe metabolism of Lobeglitazone can be increased when combined with Phenobarbital.Approved, Investigational
LobucavirThe serum concentration of Lobucavir can be decreased when it is combined with Phenobarbital.Investigational
LofentanilThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Lofentanil.Illicit
LofepramineThe metabolism of Lofepramine can be increased when combined with Phenobarbital.Experimental
LofexidineThe therapeutic efficacy of Phenobarbital can be increased when used in combination with Lofexidine.Approved, Investigational
LomerizineThe metabolism of Lomerizine can be increased when combined with Phenobarbital.Experimental
LomitapideThe metabolism of Lomitapide can be increased when combined with Phenobarbital.Approved, Investigational
LonafarnibThe serum concentration of Phenobarbital can be increased when it is combined with Lonafarnib.Investigational
LoperamideThe metabolism of Loperamide can be increased when combined with Phenobarbital.Approved
LopinavirThe serum concentration of Lopinavir can be decreased when it is combined with Phenobarbital.Approved
LoprazolamThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Loprazolam.Experimental
LoratadineThe metabolism of Loratadine can be increased when combined with Phenobarbital.Approved, Investigational
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Phenobarbital.Approved
LorcaserinThe metabolism of Lorcaserin can be increased when combined with Phenobarbital.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Lormetazepam.Approved
LorpiprazoleThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Lorpiprazole.Approved
LortalamineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Lortalamine.Experimental
LosartanThe serum concentration of Losartan can be decreased when it is combined with Phenobarbital.Approved
LoteprednolThe metabolism of Loteprednol can be increased when combined with Phenobarbital.Approved
LovastatinThe serum concentration of Lovastatin can be decreased when it is combined with Phenobarbital.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Phenobarbital.Approved
LuliconazoleThe serum concentration of Phenobarbital can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Phenobarbital can be decreased when it is combined with Lumacaftor.Approved
LumateperoneThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Lumateperone.Investigational
LumefantrineThe serum concentration of Lumefantrine can be decreased when it is combined with Phenobarbital.Approved
LurasidoneThe serum concentration of Lurasidone can be decreased when it is combined with Phenobarbital.Approved, Investigational
LusutrombopagThe serum concentration of Phenobarbital can be increased when it is combined with Lusutrombopag.Approved, Investigational
LymecyclineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Lymecycline.Approved, Investigational
LynestrenolThe therapeutic efficacy of Lynestrenol can be decreased when used in combination with Phenobarbital.Approved, Investigational
Lysergic Acid DiethylamideThe metabolism of Lysergic Acid Diethylamide can be increased when combined with Phenobarbital.Illicit, Investigational, Withdrawn
m-ChlorophenylpiperazineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with m-Chlorophenylpiperazine.Investigational
MacimorelinThe serum concentration of Macimorelin can be decreased when it is combined with Phenobarbital.Approved, Investigational
MacitentanThe serum concentration of Macitentan can be decreased when it is combined with Phenobarbital.Approved
Magnesium acetateThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Magnesium acetate.Approved
Magnesium acetate tetrahydrateThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Magnesium acetate tetrahydrate.Approved
Magnesium Aluminum SilicateThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Magnesium Aluminum Silicate.Approved
Magnesium aspartateThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Magnesium aspartate.Experimental
Magnesium carbonateThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Magnesium carbonate.Approved, Investigational
Magnesium cationThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Magnesium cation.Approved, Nutraceutical
Magnesium chlorideThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Magnesium chloride.Approved
Magnesium citrateThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Magnesium citrate.Approved
Magnesium gluconateThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Magnesium gluconate.Approved, Investigational
Magnesium glycinateThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Magnesium glycinate.Approved
Magnesium hydroxideThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Magnesium hydroxide.Approved, Investigational
Magnesium orotateThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Magnesium orotate.Experimental
Magnesium oxideThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Magnesium oxide.Approved
Magnesium phosphateThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Magnesium phosphate.Experimental
Magnesium silicateThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Magnesium silicate.Approved
Magnesium stearateThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Magnesium stearate.Investigational
Magnesium sulfateThe therapeutic efficacy of Phenobarbital can be increased when used in combination with Magnesium sulfate.Approved, Investigational, Vet Approved
Magnesium TrisilicateThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Magnesium Trisilicate.Approved
MalathionThe therapeutic efficacy of Phenobarbital can be decreased when used in combination with Malathion.Approved, Investigational
ManidipineThe metabolism of Manidipine can be increased when combined with Phenobarbital.Approved, Investigational
MannitolPhenobarbital may increase the hypotensive activities of Mannitol.Approved, Investigational
MaprotilineThe metabolism of Maprotiline can be increased when combined with Phenobarbital.Approved, Investigational
MaravirocThe serum concentration of Maraviroc can be decreased when it is combined with Phenobarbital.Approved, Investigational
MazaticolThe risk or severity of adverse effects can be increased when Mazaticol is combined with Phenobarbital.Experimental
MazindolThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Mazindol.Approved, Investigational
MebanazineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Mebanazine.Withdrawn
MebendazoleThe metabolism of Mebendazole can be increased when combined with Phenobarbital.Approved, Vet Approved
MebeverineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Mebeverine.Approved, Investigational
MebicarThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Mebicar.Experimental
MebutamateThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Mebutamate.Approved
MecamylaminePhenobarbital may increase the hypotensive activities of Mecamylamine.Approved, Investigational
MeclizineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Medetomidine.Vet Approved
Medical CannabisThe metabolism of Medical Cannabis can be increased when combined with Phenobarbital.Experimental, Investigational
MedifoxamineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Medifoxamine.Experimental
MedrogestoneThe serum concentration of Medrogestone can be decreased when it is combined with Phenobarbital.Approved
Medroxyprogesterone acetateThe therapeutic efficacy of Medroxyprogesterone acetate can be decreased when used in combination with Phenobarbital.Approved, Investigational
MedrysoneThe metabolism of Medrysone can be increased when combined with Phenobarbital.Approved
MefloquineThe therapeutic efficacy of Phenobarbital can be decreased when used in combination with Mefloquine.Approved, Investigational
Megestrol acetateThe therapeutic efficacy of Megestrol acetate can be decreased when used in combination with Phenobarbital.Approved, Investigational, Vet Approved
MelatoninThe metabolism of Melatonin can be increased when combined with Phenobarbital.Approved, Nutraceutical, Vet Approved
MelengestrolThe metabolism of Melengestrol can be increased when combined with Phenobarbital.Vet Approved
MelitracenThe metabolism of Melitracen can be increased when combined with Phenobarbital.Experimental, Investigational
MeloxicamThe metabolism of Meloxicam can be increased when combined with Phenobarbital.Approved, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Melperone.Approved, Investigational
MentholThe metabolism of Menthol can be increased when combined with Phenobarbital.Approved
MepenzolateThe risk or severity of adverse effects can be increased when Mepenzolate is combined with Phenobarbital.Approved
MephedroneThe serum concentration of Phenobarbital can be decreased when it is combined with Mephedrone.Investigational
MephenesinThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Mephenesin.Approved
MephenoxaloneThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Mephenoxalone.Experimental
MephentermineThe serum concentration of Phenobarbital can be decreased when it is combined with Mephentermine.Approved
MephenytoinThe metabolism of Mephenytoin can be increased when combined with Phenobarbital.Investigational, Withdrawn
MepindololThe serum concentration of Mepindolol can be decreased when it is combined with Phenobarbital.Experimental
MeprednisoneThe metabolism of Meprednisone can be increased when combined with Phenobarbital.Approved, Investigational
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Phenobarbital.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Meptazinol.Experimental
MesoridazineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Mesoridazine.Approved, Investigational
MestranolThe therapeutic efficacy of Mestranol can be decreased when used in combination with Phenobarbital.Approved
MetahexamideThe metabolism of Metahexamide can be increased when combined with Phenobarbital.Experimental
MetaxaloneThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Metaxalone.Approved
MetergolineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Metergoline.Experimental
MethacyclineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Methacycline.Approved, Investigational
MethadoneThe serum concentration of Methadone can be decreased when it is combined with Phenobarbital.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Methadyl Acetate.Approved, Illicit
MethamphetamineThe serum concentration of Phenobarbital can be decreased when it is combined with Methamphetamine.Approved, Illicit
Methanesulfonyl FluorideThe therapeutic efficacy of Phenobarbital can be decreased when used in combination with Methanesulfonyl Fluoride.Investigational
MethanthelineThe risk or severity of adverse effects can be increased when Methantheline is combined with Phenobarbital.Approved, Investigational
MethapyrileneThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Methapyrilene.Withdrawn
MethaqualoneThe metabolism of Methaqualone can be increased when combined with Phenobarbital.Illicit, Withdrawn
MetharbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Metharbital.Withdrawn
MethazolamidePhenobarbital may increase the hypotensive activities of Methazolamide.Approved
MethocarbamolThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Phenobarbital.Approved
MethotrimeprazinePhenobarbital may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
MethoxsalenThe metabolism of Methoxsalen can be increased when combined with Phenobarbital.Approved
MethoxyfluraneThe metabolism of Methoxyflurane can be increased when combined with Phenobarbital.Approved, Investigational, Vet Approved
MethoxyphenamineThe serum concentration of Phenobarbital can be decreased when it is combined with Methoxyphenamine.Experimental
MethscopolamineThe risk or severity of adverse effects can be increased when Methscopolamine is combined with Phenobarbital.Approved
MethsuximideThe metabolism of Methsuximide can be increased when combined with Phenobarbital.Approved
MethyclothiazideThe risk or severity of hypotension and orthostatic hypotension can be increased when Phenobarbital is combined with Methyclothiazide.Approved
MethyldopaPhenobarbital may increase the hypotensive activities of Methyldopa.Approved
Methylene blueThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Methylene blue.Approved, Investigational
MethylergometrineThe metabolism of Methylergometrine can be increased when combined with Phenobarbital.Approved
MethylpentynolThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Methylpentynol.Experimental
MethylphenidateThe serum concentration of Phenobarbital can be increased when it is combined with Methylphenidate.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Methylphenobarbital.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be decreased when it is combined with Phenobarbital.Approved, Vet Approved
Methylscopolamine bromideThe risk or severity of adverse effects can be increased when Methylscopolamine bromide is combined with Phenobarbital.Approved
MethyltestosteroneThe metabolism of Methyltestosterone can be increased when combined with Phenobarbital.Approved
MethyprylonThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Methyprylon.Approved, Illicit, Withdrawn
MethysergideThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Methysergide.Approved
MetipranololPhenobarbital may increase the hypotensive activities of Metipranolol.Approved
MetixeneThe risk or severity of adverse effects can be increased when Metixene is combined with Phenobarbital.Approved
MetoclopramideThe therapeutic efficacy of Phenobarbital can be decreased when used in combination with Metoclopramide.Approved, Investigational
MetocurineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Metocurine.Approved
Metocurine IodideThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Metocurine Iodide.Approved, Withdrawn
MetolazoneThe risk or severity of hypotension and orthostatic hypotension can be increased when Phenobarbital is combined with Metolazone.Approved
MetoprololPhenobarbital may increase the hypotensive activities of Metoprolol.Approved, Investigational
MetyrosinePhenobarbital may increase the sedative activities of Metyrosine.Approved
MexiletineThe metabolism of Mexiletine can be increased when combined with Phenobarbital.Approved, Investigational
MianserinMianserin may increase the central nervous system depressant (CNS depressant) activities of Phenobarbital.Approved, Investigational
MibefradilThe metabolism of Mibefradil can be increased when combined with Phenobarbital.Investigational, Withdrawn
MiconazoleThe metabolism of Miconazole can be increased when combined with Phenobarbital.Approved, Investigational, Vet Approved
MicronomicinThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Micronomicin.Experimental
MidazolamThe metabolism of Midazolam can be increased when combined with Phenobarbital.Approved, Illicit
MidecamycinThe metabolism of Midecamycin can be increased when combined with Phenobarbital.Approved
MidomafetamineThe serum concentration of Phenobarbital can be decreased when it is combined with Midomafetamine.Experimental, Illicit, Investigational
MidostaurinThe metabolism of Midostaurin can be increased when combined with Phenobarbital.Approved, Investigational
MifepristoneThe serum concentration of Mifepristone can be decreased when it is combined with Phenobarbital.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Milnacipran.Approved, Investigational
MinaprineThe therapeutic efficacy of Phenobarbital can be decreased when used in combination with Minaprine.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Phenobarbital.Approved, Investigational
MinoxidilPhenobarbital may increase the hypotensive activities of Minoxidil.Approved, Investigational
MirabegronThe metabolism of Mirabegron can be increased when combined with Phenobarbital.Approved
MirtazapinePhenobarbital may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitotaneThe serum concentration of Phenobarbital can be increased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Phenobarbital can be increased when it is combined with Mitoxantrone.Approved, Investigational
MivacuriumThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Mivacurium.Approved
MK-212The risk or severity of adverse effects can be increased when Phenobarbital is combined with MK-212.Investigational
MMDAThe serum concentration of Phenobarbital can be decreased when it is combined with MMDA.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Moclobemide.Approved, Investigational
ModafinilThe metabolism of Modafinil can be increased when combined with Phenobarbital.Approved, Investigational
MoexiprilPhenobarbital may increase the hypotensive activities of Moexipril.Approved
MolindoneThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Molindone.Approved
MometasoneThe metabolism of Mometasone can be increased when combined with Phenobarbital.Approved, Vet Approved
Mometasone furoateThe metabolism of Mometasone furoate can be increased when combined with Phenobarbital.Approved, Vet Approved
MonensinThe serum concentration of Phenobarbital can be increased when it is combined with Monensin.Vet Approved
MontelukastThe metabolism of Montelukast can be increased when combined with Phenobarbital.Approved
MoperoneThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Moperone.Experimental
MoricizineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Moricizine.Approved, Investigational, Withdrawn
MorphineThe serum concentration of Morphine can be decreased when it is combined with Phenobarbital.Approved, Investigational
MosapramineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Mosapramine.Experimental
MosaprideThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Mosapride.Investigational
MoxonidinePhenobarbital may increase the hypotensive activities of Moxonidine.Approved, Investigational
MRK-409The risk or severity of adverse effects can be increased when Phenobarbital is combined with MRK-409.Experimental
MuraglitazarThe serum concentration of Muraglitazar can be decreased when it is combined with Phenobarbital.Investigational
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Phenobarbital.Approved, Investigational
Mycophenolic acidThe serum concentration of Mycophenolic acid can be decreased when it is combined with Phenobarbital.Approved
N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine.Experimental
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Phenobarbital.Approved, Investigational
NabiximolsThe metabolism of Nabiximols can be increased when combined with Phenobarbital.Approved, Investigational
NabumetoneThe metabolism of Nabumetone can be increased when combined with Phenobarbital.Approved
NadololPhenobarbital may increase the hypotensive activities of Nadolol.Approved
NaftidrofurylThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Naftidrofuryl.Experimental
NaftopidilThe metabolism of Naftopidil can be increased when combined with Phenobarbital.Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Phenobarbital.Approved
NaloxegolThe serum concentration of Naloxegol can be decreased when it is combined with Phenobarbital.Approved
NaloxoneThe serum concentration of Naloxone can be decreased when it is combined with Phenobarbital.Approved, Vet Approved
NaltrexoneThe serum concentration of Naltrexone can be decreased when it is combined with Phenobarbital.Approved, Investigational, Vet Approved
NaluzotanThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Naluzotan.Investigational
NaproxenThe serum concentration of Naproxen can be decreased when it is combined with Phenobarbital.Approved, Vet Approved
NaratriptanThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Naratriptan.Approved, Investigational
NaronaprideThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Naronapride.Investigational
NateglinideThe metabolism of Nateglinide can be increased when combined with Phenobarbital.Approved, Investigational
NeamineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Neamine.Experimental
NebivololPhenobarbital may increase the hypotensive activities of Nebivolol.Approved, Investigational
NefazodoneThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Nefazodone.Approved, Withdrawn
NefiracetamThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Nefiracetam.Investigational
NelfinavirThe serum concentration of Phenobarbital can be increased when it is combined with Nelfinavir.Approved
NeocitrullamonThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Neocitrullamon.Experimental
NeomycinThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Neomycin.Approved, Vet Approved
NeosaxitoxinThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Neosaxitoxin.Investigational
NeostigmineThe therapeutic efficacy of Phenobarbital can be decreased when used in combination with Neostigmine.Approved, Vet Approved
NeratinibThe metabolism of Neratinib can be increased when combined with Phenobarbital.Approved, Investigational
NesiritidePhenobarbital may increase the hypotensive activities of Nesiritide.Approved, Investigational
NetilmicinThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Netilmicin.Approved, Investigational
NetoglitazoneThe metabolism of Netoglitazone can be increased when combined with Phenobarbital.Experimental
NetupitantThe serum concentration of Netupitant can be decreased when it is combined with Phenobarbital.Approved, Investigational
NevirapineThe metabolism of Nevirapine can be increased when combined with Phenobarbital.Approved
NialamideThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Nialamide.Withdrawn
NiaprazineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Niaprazine.Experimental
NicardipinePhenobarbital may increase the hypotensive activities of Nicardipine.Approved, Investigational
NicomorphineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Nicomorphine.Experimental
NicotineThe metabolism of Nicotine can be increased when combined with Phenobarbital.Approved
NifedipineThe serum concentration of Nifedipine can be decreased when it is combined with Phenobarbital.Approved
NigericinThe serum concentration of Phenobarbital can be increased when it is combined with Nigericin.Experimental
NiguldipineThe metabolism of Niguldipine can be increased when combined with Phenobarbital.Experimental
NilotinibThe serum concentration of Nilotinib can be decreased when it is combined with Phenobarbital.Approved, Investigational
NiludipineThe metabolism of Niludipine can be increased when combined with Phenobarbital.Experimental
NilvadipinePhenobarbital may increase the hypotensive activities of Nilvadipine.Approved, Investigational
NimesulideThe metabolism of Nimesulide can be increased when combined with Phenobarbital.Approved, Investigational, Withdrawn
NimodipineThe serum concentration of Nimodipine can be decreased when it is combined with Phenobarbital.Approved, Investigational
NintedanibThe serum concentration of Nintedanib can be decreased when it is combined with Phenobarbital.Approved
NisoldipineThe serum concentration of Nisoldipine can be decreased when it is combined with Phenobarbital.Approved
NisoxetineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Nisoxetine.Experimental
NitrazepamThe metabolism of Nitrazepam can be increased when combined with Phenobarbital.Approved
NitrendipinePhenobarbital may increase the hypotensive activities of Nitrendipine.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Phenobarbital.Approved
NitroglycerinPhenobarbital may increase the hypotensive activities of Nitroglycerin.Approved, Investigational
NitroprussidePhenobarbital may increase the hypotensive activities of Nitroprusside.Approved, Investigational
Nitrous acidThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Nitrous acid.Approved, Investigational
Nitrous oxideThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Nitrous oxide.Approved, Vet Approved
NomegestrolThe metabolism of Nomegestrol can be increased when combined with Phenobarbital.Approved
Nomegestrol acetateThe therapeutic efficacy of Nomegestrol acetate can be decreased when used in combination with Phenobarbital.Approved, Investigational
NomifensineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Nomifensine.Withdrawn
NordazepamThe metabolism of Nordazepam can be increased when combined with Phenobarbital.Approved
NorelgestrominThe therapeutic efficacy of Norelgestromin can be decreased when used in combination with Phenobarbital.Approved, Investigational
NorethisteroneThe therapeutic efficacy of Norethisterone can be decreased when used in combination with Phenobarbital.Approved
NorethynodrelThe therapeutic efficacy of Norethynodrel can be decreased when used in combination with Phenobarbital.Approved
NorgestimateThe therapeutic efficacy of Norgestimate can be decreased when used in combination with Phenobarbital.Approved, Investigational
NorgestrelThe therapeutic efficacy of Norgestrel can be decreased when used in combination with Phenobarbital.Approved
NorgestrienoneThe therapeutic efficacy of Norgestrienone can be decreased when used in combination with Phenobarbital.Experimental
NormethadoneThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Normethadone.Approved, Illicit
NortriptylineThe metabolism of Nortriptyline can be increased when combined with Phenobarbital.Approved
NylidrinThe metabolism of Nylidrin can be increased when combined with Phenobarbital.Approved
ObinutuzumabPhenobarbital may increase the hypotensive activities of Obinutuzumab.Approved, Investigational
OctamoxinThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Octamoxin.Withdrawn
OdanacatibThe metabolism of Odanacatib can be increased when combined with Phenobarbital.Investigational
OlanzapineThe serum concentration of Olanzapine can be decreased when it is combined with Phenobarbital.Approved, Investigational
OlaparibThe serum concentration of Olaparib can be decreased when it is combined with Phenobarbital.Approved
OlmesartanPhenobarbital may increase the hypotensive activities of Olmesartan.Approved, Investigational
OlopatadineThe metabolism of Olopatadine can be increased when combined with Phenobarbital.Approved
OmbitasvirThe serum concentration of Ombitasvir can be decreased when it is combined with Phenobarbital.Approved, Investigational
OmeprazoleThe metabolism of Omeprazole can be increased when combined with Phenobarbital.Approved, Investigational, Vet Approved
OndansetronThe metabolism of Ondansetron can be increased when combined with Phenobarbital.Approved
ONT-093The serum concentration of Phenobarbital can be increased when it is combined with ONT-093.Investigational
OpipramolThe metabolism of Opipramol can be increased when combined with Phenobarbital.Investigational
OpiumThe metabolism of Opium can be increased when combined with Phenobarbital.Approved, Illicit
OrlistatOrlistat can cause a decrease in the absorption of Phenobarbital resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
OrphenadrinePhenobarbital may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OrvepitantThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Orvepitant.Investigational
OsanetantThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Osimertinib can be decreased when it is combined with Phenobarbital.Approved
OspemifeneThe metabolism of Ospemifene can be increased when combined with Phenobarbital.Approved, Investigational
OtiloniumThe metabolism of Otilonium can be increased when combined with Phenobarbital.Experimental, Investigational
OxaflozaneThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Oxaflozane.Experimental
OxaprotilineThe metabolism of Oxaprotiline can be increased when combined with Phenobarbital.Experimental
OxazepamThe metabolism of Oxazepam can be increased when combined with Phenobarbital.Approved
OxcarbazepineThe serum concentration of 10-monohydroxy derivative of oxcarbazepine (MHD), an active metabolite of Oxcarbazepine, can be decreased when used in combination with Phenobarbital.Approved
OxiracetamThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Oxiracetam.Experimental
OxitriptanThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Oxitriptan.Approved, Investigational, Nutraceutical
OxitropiumThe risk or severity of adverse effects can be increased when Oxitropium is combined with Phenobarbital.Investigational
OxprenololPhenobarbital may increase the hypotensive activities of Oxprenolol.Approved
OxtriphyllineThe serum concentration of Oxtriphylline can be decreased when it is combined with Phenobarbital.Approved
OxybutyninThe metabolism of Oxybutynin can be increased when combined with Phenobarbital.Approved, Investigational
OxycodoneThe metabolism of Oxycodone can be increased when combined with Phenobarbital.Approved, Illicit, Investigational
OxymorphoneThe metabolism of Oxymorphone can be increased when combined with Phenobarbital.Approved, Investigational, Vet Approved
OxypertineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Oxypertine.Experimental
OxyphencyclimineThe risk or severity of adverse effects can be increased when Oxyphencyclimine is combined with Phenobarbital.Approved
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Phenobarbital.Approved
OxytetracyclineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Oxytetracycline.Approved, Investigational, Vet Approved
PaclitaxelPhenobarbital may increase the hypotensive activities of Paclitaxel.Approved, Vet Approved
PalbociclibThe serum concentration of Palbociclib can be decreased when it is combined with Phenobarbital.Approved, Investigational
PaliperidoneThe serum concentration of Paliperidone can be decreased when it is combined with Phenobarbital.Approved
PalonosetronThe metabolism of Palonosetron can be increased when combined with Phenobarbital.Approved, Investigational
PancuroniumThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Pancuronium.Approved
PanobinostatThe serum concentration of Panobinostat can be decreased when it is combined with Phenobarbital.Approved, Investigational
PantoprazoleThe metabolism of Pantoprazole can be increased when combined with Phenobarbital.Approved
PapaverinePhenobarbital may increase the hypotensive activities of Papaverine.Approved, Investigational
ParaldehydePhenobarbital may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParamethadioneThe metabolism of Paramethadione can be increased when combined with Phenobarbital.Approved
ParamethasoneThe metabolism of Paramethasone can be increased when combined with Phenobarbital.Approved
ParaoxonThe therapeutic efficacy of Phenobarbital can be decreased when used in combination with Paraoxon.Experimental
ParecoxibThe metabolism of Parecoxib can be increased when combined with Phenobarbital.Approved
PargylineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Pargyline.Approved
ParicalcitolThe metabolism of Paricalcitol can be increased when combined with Phenobarbital.Approved, Investigational
ParitaprevirThe serum concentration of Paritaprevir can be decreased when it is combined with Phenobarbital.Approved, Investigational
ParomomycinThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Paromomycin.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Paroxetine.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be decreased when it is combined with Phenobarbital.Approved
PefloxacinThe metabolism of Pefloxacin can be increased when combined with Phenobarbital.Approved
PeldesineThe serum concentration of Peldesine can be decreased when it is combined with Phenobarbital.Experimental, Investigational
PemetrexedThe serum concentration of Pemetrexed can be decreased when it is combined with Phenobarbital.Approved, Investigational
PenbutololPhenobarbital may increase the hypotensive activities of Penbutolol.Approved, Investigational
PenciclovirThe serum concentration of Penciclovir can be decreased when it is combined with Phenobarbital.Approved
PenfluridolThe metabolism of Penfluridol can be increased when combined with Phenobarbital.Experimental
PenimepicyclineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Penimepicycline.Experimental
PentamidineThe metabolism of Pentamidine can be increased when combined with Phenobarbital.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Phenobarbital.Approved, Vet Approved
PenthienateThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Penthienate.Experimental
PentifyllineThe serum concentration of Pentifylline can be decreased when it is combined with Phenobarbital.Experimental
PentobarbitalThe metabolism of Pentobarbital can be increased when combined with Phenobarbital.Approved, Investigational, Vet Approved
PentoliniumThe risk or severity of adverse effects can be increased when Pentolinium is combined with Phenobarbital.Approved
PentoxifyllineThe serum concentration of Pentoxifylline can be decreased when it is combined with Phenobarbital.Approved, Investigational
PerampanelThe serum concentration of Perampanel can be decreased when it is combined with Phenobarbital.Approved
PerazineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Perazine.Approved, Investigational
PergolideThe metabolism of Pergolide can be increased when combined with Phenobarbital.Approved, Investigational, Vet Approved, Withdrawn
PerhexilineThe metabolism of Perhexiline can be increased when combined with Phenobarbital.Approved, Investigational
PerindoprilPhenobarbital may increase the hypotensive activities of Perindopril.Approved
PermethrinThe metabolism of Permethrin can be increased when combined with Phenobarbital.Approved, Investigational
PerospironeThe metabolism of Perospirone can be increased when combined with Phenobarbital.Approved
PerphenazineThe metabolism of Perphenazine can be increased when combined with Phenobarbital.Approved
PethidinePhenobarbital may increase the hypotensive and central nervous system depressant (CNS depressant) activities of Pethidine.Approved
PhenacemideThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Phenacemide.Approved
PhenacetinThe metabolism of Phenacetin can be increased when combined with Phenobarbital.Withdrawn
PhenazocineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Phenazocine.Experimental
PhencyclidineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Phencyclidine.Illicit
PhenelzinePhenobarbital may increase the hypotensive activities of Phenelzine.Approved
PhenethylamineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Phenethylamine.Experimental
PheneturideThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Pheneturide.Experimental
PhenglutarimideThe risk or severity of adverse effects can be increased when Phenglutarimide is combined with Phenobarbital.Experimental
PhenibutThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Phenibut.Experimental
PhenindioneThe metabolism of Phenindione can be increased when combined with Phenobarbital.Approved, Investigational
PheniprazineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Pheniprazine.Withdrawn
PhenoperidineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Phenoperidine.Experimental
PhenoxybenzaminePhenobarbital may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Phenoxypropazine.Withdrawn
PhenprobamateThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Phenprobamate.Experimental
PhenprocoumonThe metabolism of Phenprocoumon can be increased when combined with Phenobarbital.Approved, Investigational
PhensuximideThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Phensuximide.Approved
PhentermineThe serum concentration of Phenobarbital can be decreased when it is combined with Phentermine.Approved, Illicit
PhentolaminePhenobarbital may increase the hypotensive activities of Phentolamine.Approved
PhenylbutazoneThe metabolism of Phenylbutazone can be increased when combined with Phenobarbital.Approved, Vet Approved
PhenytoinPhenytoin may increase the central nervous system depressant (CNS depressant) activities of Phenobarbital.Approved, Vet Approved
PhysostigmineThe therapeutic efficacy of Phenobarbital can be decreased when used in combination with Physostigmine.Approved, Investigational
PibrentasvirThe serum concentration of Phenobarbital can be increased when it is combined with Pibrentasvir.Approved, Investigational
PiclozotanThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Piclozotan.Investigational
PilocarpineThe metabolism of Pilocarpine can be increased when combined with Phenobarbital.Approved, Investigational
PimavanserinThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Pimavanserin.Approved, Investigational
PimecrolimusThe metabolism of Pimecrolimus can be increased when combined with Phenobarbital.Approved, Investigational
PimobendanThe metabolism of Pimobendan can be increased when combined with Phenobarbital.Vet Approved
PimozideThe metabolism of Pimozide can be increased when combined with Phenobarbital.Approved
PinacidilThe metabolism of Pinacidil can be increased when combined with Phenobarbital.Approved
PinaveriumThe metabolism of Pinaverium can be increased when combined with Phenobarbital.Approved
PinazepamThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Pinazepam.Experimental
PindololPhenobarbital may increase the hypotensive activities of Pindolol.Approved, Investigational
PioglitazoneThe metabolism of Pioglitazone can be increased when combined with Phenobarbital.Approved, Investigational
PipamperonePhenobarbital may increase the hypotensive activities of Pipamperone.Approved, Investigational
PipecuroniumThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Pipecuronium.Approved
Pipemidic acidThe metabolism of Pipemidic acid can be increased when combined with Phenobarbital.Experimental
PipenzolateThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Pipenzolate.Experimental
PiperaquineThe metabolism of Piperaquine can be increased when combined with Phenobarbital.Approved, Investigational
PiperidolateThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Piperidolate.Experimental
PipotiazineThe metabolism of Pipotiazine can be increased when combined with Phenobarbital.Approved, Investigational
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Phenobarbital.Approved
PirfenidoneThe serum concentration of Pirfenidone can be decreased when it is combined with Phenobarbital.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Piritramide.Approved, Investigational
PirlimycinThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Pirlimycin.Vet Approved
PirlindoleThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Pirlindole.Approved
PiroxicamThe metabolism of Piroxicam can be increased when combined with Phenobarbital.Approved, Investigational
PitolisantThe serum concentration of Pitolisant can be decreased when it is combined with Phenobarbital.Approved, Investigational
PivagabineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Pivagabine.Investigational
PivhydrazineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Pivhydrazine.Withdrawn
PizotifenThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Pizotifen.Approved
PlazomicinThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Plazomicin.Approved, Investigational
PodofiloxThe metabolism of Podofilox can be increased when combined with Phenobarbital.Approved
PoldineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Poldine.Experimental
Polymyxin B SulfateThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Polymyxin B Sulfate.Approved, Vet Approved
PolythiazideThe risk or severity of hypotension and orthostatic hypotension can be increased when Phenobarbital is combined with Polythiazide.Approved
PomalidomideThe metabolism of Pomalidomide can be increased when combined with Phenobarbital.Approved
PonatinibThe serum concentration of Ponatinib can be decreased when it is combined with Phenobarbital.Approved, Investigational
PosaconazoleThe metabolism of Posaconazole can be increased when combined with Phenobarbital.Approved, Investigational, Vet Approved
PractololThe serum concentration of Practolol can be decreased when it is combined with Phenobarbital.Approved
PramipexolePhenobarbital may increase the sedative activities of Pramipexole.Approved, Investigational
PrasteroneThe metabolism of Prasterone can be increased when combined with Phenobarbital.Approved, Investigational, Nutraceutical
PrasugrelThe metabolism of Prasugrel can be increased when combined with Phenobarbital.Approved
PravastatinThe metabolism of Pravastatin can be increased when combined with Phenobarbital.Approved
PrazepamThe metabolism of Prazepam can be increased when combined with Phenobarbital.Approved, Illicit
PraziquantelThe serum concentration of Praziquantel can be decreased when it is combined with Phenobarbital.Approved, Investigational, Vet Approved
PrazosinPhenobarbital may increase the hypotensive activities of Prazosin.Approved
PrednicarbateThe metabolism of Prednicarbate can be increased when combined with Phenobarbital.Approved, Investigational
PrednisoloneThe serum concentration of Prednisolone can be decreased when it is combined with Phenobarbital.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be decreased when it is combined with Phenobarbital.Approved, Vet Approved
PrednylideneThe metabolism of Prednylidene can be increased when combined with Phenobarbital.Experimental
PregabalinThe therapeutic efficacy of Phenobarbital can be increased when used in combination with Pregabalin.Approved, Illicit, Investigational
PregnenoloneThe metabolism of Pregnenolone can be increased when combined with Phenobarbital.Approved, Experimental, Investigational
PrenylamineThe metabolism of Prenylamine can be increased when combined with Phenobarbital.Withdrawn
PridinolThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Pridinol.Experimental
PrifiniumThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Prifinium.Experimental
PrilocaineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Prilocaine.Approved
PrimaquineThe metabolism of Primaquine can be increased when combined with Phenobarbital.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Primidone is combined with Phenobarbital.Approved, Vet Approved
ProcainamideThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Procainamide.Approved
ProcaineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Procaine.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Procarbazine.Approved, Investigational
ProchlorperazineThe metabolism of Prochlorperazine can be increased when combined with Phenobarbital.Approved, Vet Approved
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Phenobarbital.Approved
ProgabideThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Progabide.Approved, Investigational
ProgesteroneThe metabolism of Progesterone can be increased when combined with Phenobarbital.Approved, Vet Approved
ProguanilThe metabolism of Proguanil can be increased when combined with Phenobarbital.Approved
PromazineThe metabolism of Promazine can be increased when combined with Phenobarbital.Approved, Vet Approved
PromegestoneThe metabolism of Promegestone can be increased when combined with Phenobarbital.Experimental
PromethazineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Promethazine.Approved, Investigational
PropacetamolThe metabolism of Propacetamol can be increased when combined with Phenobarbital.Approved, Investigational
PropanididThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Propanidid.Experimental
PropanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with Phenobarbital.Approved
PropentofyllineThe serum concentration of Propentofylline can be decreased when it is combined with Phenobarbital.Investigational
PropericiazineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Propericiazine.Approved, Investigational
PropiomazineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Propiomazine.Approved
PropiopromazineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Propiopromazine.Vet Approved
PropiverineThe metabolism of Propiverine can be increased when combined with Phenobarbital.Approved, Investigational
PropofolThe serum concentration of Propofol can be decreased when it is combined with Phenobarbital.Approved, Investigational, Vet Approved
PropranololPhenobarbital may increase the hypotensive activities of Propranolol.Approved, Investigational
ProthipendylThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Prothipendyl.Investigational
ProtriptylineThe metabolism of Protriptyline can be increased when combined with Phenobarbital.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Proxibarbal.Experimental
ProxyphyllineThe serum concentration of Proxyphylline can be decreased when it is combined with Phenobarbital.Experimental
PRX-08066The risk or severity of adverse effects can be increased when Phenobarbital is combined with PRX-08066.Investigational
PseudoephedrineThe serum concentration of Phenobarbital can be decreased when it is combined with Pseudoephedrine.Approved
PsilocybineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Psilocybine.Investigational
PuromycinThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Puromycin.Experimental
PyrantelThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Pyrantel.Approved, Vet Approved
PyrazinamideThe metabolism of Pyrazinamide can be increased when combined with Phenobarbital.Approved, Investigational
PyridostigmineThe therapeutic efficacy of Phenobarbital can be decreased when used in combination with Pyridostigmine.Approved, Investigational
PyridoxineThe metabolism of Phenobarbital can be increased when combined with Pyridoxine.Approved, Investigational, Nutraceutical, Vet Approved
PyrithyldioneThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Pyrithyldione.Experimental
QuazepamThe metabolism of Quazepam can be increased when combined with Phenobarbital.Approved, Illicit
QuercetinThe serum concentration of Phenobarbital can be increased when it is combined with Quercetin.Experimental, Investigational
QuetiapineThe serum concentration of Quetiapine can be decreased when it is combined with Phenobarbital.Approved
QuinacrineThe metabolism of Quinacrine can be increased when combined with Phenobarbital.Approved, Investigational
QuinaprilPhenobarbital may increase the hypotensive activities of Quinapril.Approved, Investigational
QuinethazoneThe risk or severity of hypotension and orthostatic hypotension can be increased when Phenobarbital is combined with Quinethazone.Approved
QuingestanolThe therapeutic efficacy of Quingestanol can be decreased when used in combination with Phenobarbital.Experimental
QuinidinePhenobarbital may increase the hepatotoxic activities of Quinidine.Approved, Investigational
QuinineThe serum concentration of Phenobarbital can be increased when it is combined with Quinine.Approved
QuinupramineThe metabolism of Quinupramine can be increased when combined with Phenobarbital.Experimental
RabeprazoleThe metabolism of Rabeprazole can be increased when combined with Phenobarbital.Approved, Investigational
RacloprideThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Raclopride.Investigational
RaloxifeneThe serum concentration of Raloxifene can be decreased when it is combined with Phenobarbital.Approved, Investigational
RaltegravirThe serum concentration of Raltegravir can be decreased when it is combined with Phenobarbital.Approved
RamelteonThe metabolism of Ramelteon can be increased when combined with Phenobarbital.Approved, Investigational
RamiprilPhenobarbital may increase the hypotensive activities of Ramipril.Approved
RamosetronThe metabolism of Ramosetron can be increased when combined with Phenobarbital.Approved, Investigational
RanitidineThe metabolism of Ranitidine can be increased when combined with Phenobarbital.Approved
RanolazineThe serum concentration of Ranolazine can be decreased when it is combined with Phenobarbital.Approved, Investigational
RapacuroniumThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Rapacuronium.Withdrawn
RasagilinePhenobarbital may increase the hypotensive activities of Rasagiline.Approved
ReboxetineThe metabolism of Reboxetine can be increased when combined with Phenobarbital.Approved, Investigational
RegorafenibThe serum concentration of Regorafenib can be decreased when it is combined with Phenobarbital.Approved
RemacemideThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Remacemide.Investigational
RemifentanilPhenobarbital may increase the hypotensive activities of Remifentanil.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Remoxipride.Approved, Withdrawn
RenzaprideThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Renzapride.Investigational
RepaglinideThe metabolism of Repaglinide can be increased when combined with Phenobarbital.Approved, Investigational
RepinotanThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Repinotan.Investigational
ReposalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Reposal.Approved
ReserpinePhenobarbital may increase the hypotensive activities of Reserpine.Approved, Investigational
ResveratrolThe metabolism of Resveratrol can be increased when combined with Phenobarbital.Approved, Experimental, Investigational
RetapamulinThe metabolism of Retapamulin can be increased when combined with Phenobarbital.Approved
RevefenacinThe risk or severity of adverse effects can be increased when Revefenacin is combined with Phenobarbital.Investigational
Reversin 121The serum concentration of Phenobarbital can be increased when it is combined with Reversin 121.Experimental
RibociclibThe serum concentration of Ribociclib can be decreased when it is combined with Phenobarbital.Approved, Investigational
RibostamycinThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Ribostamycin.Approved, Investigational
RifabutinThe metabolism of Rifabutin can be increased when combined with Phenobarbital.Approved, Investigational
RifampicinThe metabolism of Rifampicin can be increased when combined with Phenobarbital.Approved
RifamycinThe metabolism of Rifamycin can be increased when combined with Phenobarbital.Investigational
RifapentineThe metabolism of Rifapentine can be increased when combined with Phenobarbital.Approved, Investigational
RifaximinThe metabolism of Rifaximin can be increased when combined with Phenobarbital.Approved, Investigational
RilpivirineThe serum concentration of Rilpivirine can be decreased when it is combined with Phenobarbital.Approved
RiluzoleThe metabolism of Riluzole can be increased when combined with Phenobarbital.Approved, Investigational
RimexoloneThe metabolism of Rimexolone can be increased when combined with Phenobarbital.Approved
RimonabantThe metabolism of Rimonabant can be increased when combined with Phenobarbital.Approved, Investigational
RiociguatPhenobarbital may increase the hypotensive activities of Riociguat.Approved
RisperidoneThe metabolism of Risperidone can be increased when combined with Phenobarbital.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Ritanserin.Investigational
RitobegronThe serum concentration of Phenobarbital can be decreased when it is combined with Ritobegron.Investigational
RitonavirThe serum concentration of Ritonavir can be decreased when it is combined with Phenobarbital.Approved, Investigational
RivaroxabanThe serum concentration of Rivaroxaban can be decreased when it is combined with Phenobarbital.Approved
RivastigmineThe therapeutic efficacy of Phenobarbital can be decreased when used in combination with Rivastigmine.Approved, Investigational
RivoglitazoneThe metabolism of Rivoglitazone can be increased when combined with Phenobarbital.Experimental, Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Rizatriptan.Approved
RociverineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Rociverine.Experimental
RocuroniumThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Rocuronium.Approved
RofecoxibThe metabolism of Rofecoxib can be increased when combined with Phenobarbital.Approved, Investigational, Withdrawn
RoflumilastThe serum concentration of Roflumilast can be decreased when it is combined with Phenobarbital.Approved
RolapitantThe serum concentration of Rolapitant can be decreased when it is combined with Phenobarbital.Approved, Investigational
RolipramThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Rolipram.Investigational
RolitetracyclineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Rolitetracycline.Approved
RomidepsinThe serum concentration of Romidepsin can be decreased when it is combined with Phenobarbital.Approved, Investigational
RomifidineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Romifidine.Vet Approved
RopinirolePhenobarbital may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacainePhenobarbital may increase the hypotensive activities of Ropivacaine.Approved
RosiglitazoneThe metabolism of Rosiglitazone can be increased when combined with Phenobarbital.Approved, Investigational
RosuvastatinThe metabolism of Rosuvastatin can be increased when combined with Phenobarbital.Approved
RotigotinePhenobarbital may increase the sedative activities of Rotigotine.Approved
RoxithromycinThe metabolism of Roxithromycin can be increased when combined with Phenobarbital.Approved, Investigational, Withdrawn
RP-5063The risk or severity of adverse effects can be increased when Phenobarbital is combined with RP-5063.Investigational
RucaparibThe metabolism of Rucaparib can be increased when combined with Phenobarbital.Approved, Investigational
RufinamideThe serum concentration of Phenobarbital can be increased when it is combined with Rufinamide.Approved
RupatadineThe metabolism of Rupatadine can be increased when combined with Phenobarbital.Approved
RuxolitinibThe metabolism of Ruxolitinib can be increased when combined with Phenobarbital.Approved
SacubitrilPhenobarbital may increase the hypotensive activities of Sacubitril.Approved
SafinamideThe metabolism of Safinamide can be increased when combined with Phenobarbital.Approved, Investigational
SafrazineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Safrazine.Withdrawn
SalinomycinThe serum concentration of Phenobarbital can be increased when it is combined with Salinomycin.Vet Approved
SalmeterolThe metabolism of Salmeterol can be increased when combined with Phenobarbital.Approved
SaquinavirThe serum concentration of Phenobarbital can be increased when it is combined with Saquinavir.Approved, Investigational
SaredutantThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Saredutant.Investigational
SarpogrelateThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Sarpogrelate.Investigational
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Phenobarbital.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Scopolamine.Approved, Investigational
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Phenobarbital.Approved, Vet Approved
Secretin humanThe therapeutic efficacy of Secretin human can be decreased when used in combination with Phenobarbital.Approved
Secretin porcineThe therapeutic efficacy of Secretin porcine can be decreased when used in combination with Phenobarbital.Approved
SelegilinePhenobarbital may increase the hypotensive activities of Selegiline.Approved, Investigational, Vet Approved
SeletracetamThe metabolism of Seletracetam can be increased when combined with Phenobarbital.Investigational
SelexipagThe metabolism of Selexipag can be increased when combined with Phenobarbital.Approved
SeratrodastThe metabolism of Seratrodast can be increased when combined with Phenobarbital.Approved
SerotoninThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Serotonin.Investigational, Nutraceutical
SertindoleThe metabolism of Sertindole can be increased when combined with Phenobarbital.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Sertraline.Approved
SevofluranePhenobarbital may increase the hypotensive activities of Sevoflurane.Approved, Vet Approved
SibutramineThe metabolism of Sibutramine can be increased when combined with Phenobarbital.Approved, Illicit, Investigational, Withdrawn
SildenafilThe metabolism of Sildenafil can be increased when combined with Phenobarbital.Approved, Investigational
SilodosinThe metabolism of Silodosin can be increased when combined with Phenobarbital.Approved
SimeprevirThe serum concentration of Simeprevir can be decreased when it is combined with Phenobarbital.Approved
SimvastatinThe serum concentration of Simvastatin can be decreased when it is combined with Phenobarbital.Approved
SirolimusThe metabolism of Sirolimus can be increased when combined with Phenobarbital.Approved, Investigational
SisomicinThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Sisomicin.Investigational
SitagliptinThe metabolism of Sitagliptin can be increased when combined with Phenobarbital.Approved, Investigational
Sodium oxybatePhenobarbital may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.Approved
SofosbuvirThe serum concentration of Sofosbuvir can be decreased when it is combined with Phenobarbital.Approved
SolifenacinThe metabolism of Solifenacin can be increased when combined with Phenobarbital.Approved
SomatostatinThe risk or severity of adverse effects can be increased when Somatostatin is combined with Phenobarbital.Approved, Investigational
SonidegibThe serum concentration of Sonidegib can be decreased when it is combined with Phenobarbital.Approved, Investigational
SorafenibThe serum concentration of Sorafenib can be decreased when it is combined with Phenobarbital.Approved, Investigational
SotalolPhenobarbital may increase the hypotensive activities of Sotalol.Approved
SpiramycinThe metabolism of Spiramycin can be increased when combined with Phenobarbital.Approved
SpironolactonePhenobarbital may increase the hypotensive activities of Spironolactone.Approved
St. John's WortThe risk or severity of adverse effects can be increased when Phenobarbital is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StaurosporineThe serum concentration of Phenobarbital can be increased when it is combined with Staurosporine.Experimental
StiripentolThe serum concentration of Stiripentol can be decreased when it is combined with Phenobarbital.Approved
StreptokinasePhenobarbital may increase the hypotensive activities of Streptokinase.Approved, Investigational
StreptomycinThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Streptomycin.Approved, Vet Approved
StyramateThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Styramate.Experimental
SuccinylcholineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Succinylcholine.Approved
SufentanilPhenobarbital may increase the hypotensive activities of Sufentanil.Approved, Investigational
SulfadiazineThe metabolism of Sulfadiazine can be increased when combined with Phenobarbital.Approved, Investigational, Vet Approved
SulfamethoxazoleThe metabolism of Sulfamethoxazole can be increased when combined with Phenobarbital.Approved
SulfinpyrazoneThe metabolism of Sulfinpyrazone can be increased when combined with Phenobarbital.Approved
SulpirideThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Sulpiride.Approved, Investigational
SulthiameThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Sulthiame.Experimental
SultoprideThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Sultopride.Experimental
SumatriptanThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Sumatriptan.Approved, Investigational
SunitinibThe serum concentration of Sunitinib can be decreased when it is combined with Phenobarbital.Approved, Investigational
SuprofenThe serum concentration of Suprofen can be decreased when it is combined with Phenobarbital.Approved, Withdrawn
SuvorexantThe serum concentration of Suvorexant can be decreased when it is combined with Phenobarbital.Approved, Investigational
Synthetic Conjugated Estrogens, AThe metabolism of Synthetic Conjugated Estrogens, A can be increased when combined with Phenobarbital.Approved
Synthetic Conjugated Estrogens, BThe metabolism of Synthetic Conjugated Estrogens, B can be increased when combined with Phenobarbital.Approved
TacrineThe therapeutic efficacy of Phenobarbital can be decreased when used in combination with Tacrine.Investigational, Withdrawn
TacrolimusThe metabolism of Tacrolimus can be increased when combined with Phenobarbital.Approved, Investigational
TadalafilThe serum concentration of Tadalafil can be decreased when it is combined with Phenobarbital.Approved, Investigational
TalbutalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Talbutal.Approved, Illicit
TalinololThe serum concentration of Talinolol can be decreased when it is combined with Phenobarbital.Investigational
TalopramThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Talopram.Experimental
TamoxifenThe metabolism of Tamoxifen can be increased when combined with Phenobarbital.Approved
TamsulosinPhenobarbital may increase the hypotensive activities of Tamsulosin.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Phenobarbital.Approved
TariquidarThe serum concentration of Phenobarbital can be increased when it is combined with Tariquidar.Investigational
TasimelteonThe serum concentration of Tasimelteon can be decreased when it is combined with Phenobarbital.Approved, Investigational
TasosartanThe metabolism of Tasosartan can be increased when combined with Phenobarbital.Approved
Taurochenodeoxycholic acidThe metabolism of Taurochenodeoxycholic acid can be increased when combined with Phenobarbital.Experimental
TD-8954The risk or severity of adverse effects can be increased when Phenobarbital is combined with TD-8954.Investigational
Tedizolid phosphateThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Tedizolid phosphate.Approved
TegafurThe metabolism of Tegafur can be increased when combined with Phenobarbital.Approved, Investigational
TegaserodThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Tegaserod.Approved, Investigational, Withdrawn
TelithromycinThe metabolism of Telithromycin can be increased when combined with Phenobarbital.Approved
TelmisartanPhenobarbital may increase the hypotensive activities of Telmisartan.Approved, Investigational
TemazepamThe metabolism of Temazepam can be increased when combined with Phenobarbital.Approved, Investigational
TemsirolimusThe metabolism of Temsirolimus can be increased when combined with Phenobarbital.Approved
TeniposideThe serum concentration of Teniposide can be decreased when it is combined with Phenobarbital.Approved
TerazosinPhenobarbital may increase the hypotensive activities of Terazosin.Approved
TerbinafineThe metabolism of Terbinafine can be increased when combined with Phenobarbital.Approved, Investigational, Vet Approved
TerfenadineThe metabolism of Terfenadine can be increased when combined with Phenobarbital.Approved, Withdrawn
TergurideThe metabolism of Terguride can be increased when combined with Phenobarbital.Experimental
TerodilineThe metabolism of Terodiline can be increased when combined with Phenobarbital.Experimental
TertatololThe serum concentration of Tertatolol can be decreased when it is combined with Phenobarbital.Experimental
TesmilifeneThe metabolism of Tesmilifene can be increased when combined with Phenobarbital.Investigational
TestosteroneThe metabolism of Testosterone can be increased when combined with Phenobarbital.Approved, Investigational
Testosterone cypionateThe metabolism of Testosterone cypionate can be increased when combined with Phenobarbital.Approved
Testosterone enanthateThe metabolism of Testosterone enanthate can be increased when combined with Phenobarbital.Approved
Testosterone propionateThe metabolism of Testosterone propionate can be increased when combined with Phenobarbital.Approved, Investigational, Vet Approved, Withdrawn
Testosterone undecanoateThe metabolism of Testosterone undecanoate can be increased when combined with Phenobarbital.Approved, Investigational
TetracosactideTetracosactide may increase the hepatotoxic activities of Phenobarbital.Approved
TetracyclineThe metabolism of Tetracycline can be increased when combined with Phenobarbital.Approved, Vet Approved
TetrahydrocannabivarinThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Tetrahydrocannabivarin.Investigational
TetrahydropalmatineThe metabolism of Tetrahydropalmatine can be increased when combined with Phenobarbital.Investigational
TetrandrineThe metabolism of Tetrandrine can be increased when combined with Phenobarbital.Experimental
TetrazepamThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Tetrazepam.Experimental
TetrodotoxinThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Tetrodotoxin.Investigational
TezacaftorThe serum concentration of Tezacaftor can be decreased when it is combined with Phenobarbital.Approved, Investigational
ThalidomidePhenobarbital may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheobromineThe serum concentration of Theobromine can be decreased when it is combined with Phenobarbital.Approved, Investigational
TheodrenalineThe serum concentration of Theodrenaline can be decreased when it is combined with Phenobarbital.Investigational
TheophyllineThe metabolism of Theophylline can be increased when combined with Phenobarbital.Approved
ThiamylalThe metabolism of Thiamylal can be increased when combined with Phenobarbital.Approved, Vet Approved
ThiazinamThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Thiazinam.Experimental
ThiethylperazineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Thiethylperazine.Withdrawn
ThiocolchicosideThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Thiocolchicoside.Approved, Investigational
ThiopentalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Thiopental.Approved, Vet Approved
ThiopropazateThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Thiopropazate.Experimental
ThioproperazineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Thioproperazine.Approved
ThioridazinePhenobarbital may increase the hypotensive activities of Thioridazine.Approved, Withdrawn
ThiotepaThe metabolism of Thiotepa can be increased when combined with Phenobarbital.Approved, Investigational
ThiothixeneThe metabolism of Thiothixene can be increased when combined with Phenobarbital.Approved
ThonzylamineThe risk or severity of adverse effects can be increased when Thonzylamine is combined with Phenobarbital.Approved
TiagabineThe serum concentration of Tiagabine can be decreased when it is combined with Phenobarbital.Approved, Investigational
TianeptineThe metabolism of Tianeptine can be increased when combined with Phenobarbital.Approved, Investigational
TiaprideThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Tiapride.Approved, Investigational
TicagrelorThe serum concentration of Ticagrelor can be decreased when it is combined with Phenobarbital.Approved
TiclopidineThe metabolism of Ticlopidine can be increased when combined with Phenobarbital.Approved
Tiemonium iodideThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Tiemonium iodide.Experimental
TigecyclineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Tigecycline.Approved
TiletamineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Tilidine.Experimental
TimepidiumThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Timepidium.Experimental
TimololPhenobarbital may increase the hypotensive activities of Timolol.Approved
TinidazoleThe metabolism of Tinidazole can be increased when combined with Phenobarbital.Approved, Investigational
TioclomarolThe metabolism of Tioclomarol can be increased when combined with Phenobarbital.Experimental
TiotropiumThe metabolism of Tiotropium can be increased when combined with Phenobarbital.Approved
TipifarnibThe serum concentration of Phenobarbital can be increased when it is combined with Tipifarnib.Investigational
TipranavirThe serum concentration of Tipranavir can be decreased when it is combined with Phenobarbital.Approved, Investigational
TizanidinePhenobarbital may increase the hypotensive activities of Tizanidine.Approved, Investigational
TobramycinThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Tobramycin.Approved, Investigational
TocofersolanThe metabolism of Tocofersolan can be increased when combined with Phenobarbital.Approved
TocopherolThe metabolism of Tocopherol can be increased when combined with Phenobarbital.Approved, Investigational
TofacitinibThe serum concentration of Tofacitinib can be decreased when it is combined with Phenobarbital.Approved, Investigational
TofisopamThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Tofisopam.Approved
TolazamideThe metabolism of Tolazamide can be increased when combined with Phenobarbital.Approved, Investigational
TolazolinePhenobarbital may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolbutamideThe metabolism of Tolbutamide can be increased when combined with Phenobarbital.Approved, Investigational
TolcaponePhenobarbital may increase the hypotensive activities of Tolcapone.Approved, Withdrawn
Tolfenamic AcidThe metabolism of Tolfenamic Acid can be increased when combined with Phenobarbital.Approved, Investigational
ToloxatoneThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Toloxatone.Approved
TolperisoneThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Tolperisone.Approved, Investigational
TolterodineThe metabolism of Tolterodine can be increased when combined with Phenobarbital.Approved, Investigational
TolvaptanThe serum concentration of Tolvaptan can be decreased when it is combined with Phenobarbital.Approved
TopiramateThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Topiramate.Approved
TorasemidePhenobarbital may increase the hypotensive activities of Torasemide.Approved
ToremifeneThe serum concentration of Toremifene can be decreased when it is combined with Phenobarbital.Approved, Investigational
TrabectedinThe serum concentration of Trabectedin can be decreased when it is combined with Phenobarbital.Approved, Investigational
TramadolThe serum concentration of Tramadol can be decreased when it is combined with Phenobarbital.Approved, Investigational
TramiprosateThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Tramiprosate.Investigational
TrandolaprilPhenobarbital may increase the hypotensive activities of Trandolapril.Approved
TranilastThe metabolism of Tranilast can be increased when combined with Phenobarbital.Approved, Investigational
TranylcyprominePhenobarbital may increase the hypotensive activities of Tranylcypromine.Approved, Investigational
Trastuzumab emtansineThe metabolism of Trastuzumab emtansine can be increased when combined with Phenobarbital.Approved, Investigational
TrazodoneThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Trazodone.Approved, Investigational
TreprostinilThe serum concentration of Treprostinil can be decreased when it is combined with Phenobarbital.Approved, Investigational
TretinoinPhenobarbital may increase the hypotensive activities of Tretinoin.Approved, Investigational, Nutraceutical
TriamcinoloneThe metabolism of Triamcinolone can be increased when combined with Phenobarbital.Approved, Vet Approved
TriamterenePhenobarbital may increase the hypotensive activities of Triamterene.Approved
TriazolamThe metabolism of Triazolam can be increased when combined with Phenobarbital.Approved, Investigational
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Tricaine methanesulfonate.Vet Approved
TrichlorfonThe therapeutic efficacy of Phenobarbital can be decreased when used in combination with Trichlorfon.Vet Approved
TrichlormethiazideThe risk or severity of hypotension and orthostatic hypotension can be increased when Phenobarbital is combined with Trichlormethiazide.Approved, Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Trichloroethylene.Approved
TriclofosThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Triclofos.Withdrawn
TridihexethylThe risk or severity of adverse effects can be increased when Tridihexethyl is combined with Phenobarbital.Withdrawn
TrifluoperazineThe metabolism of Trifluoperazine can be increased when combined with Phenobarbital.Approved, Investigational
TrifluperidolThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Triflupromazine.Approved, Vet Approved
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Phenobarbital.Approved
TrilostaneThe metabolism of Trilostane can be increased when combined with Phenobarbital.Approved, Investigational, Vet Approved, Withdrawn
TrimebutineThe metabolism of Trimebutine can be increased when combined with Phenobarbital.Approved
TrimethadioneThe metabolism of Trimethadione can be increased when combined with Phenobarbital.Approved
TrimethaphanThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Phenobarbital.Approved, Investigational
TrimethoprimThe metabolism of Trimethoprim can be increased when combined with Phenobarbital.Approved, Vet Approved
TrimipramineThe metabolism of Trimipramine can be increased when combined with Phenobarbital.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Triprolidine.Approved
TroglitazoneThe serum concentration of Troglitazone can be decreased when it is combined with Phenobarbital.Investigational, Withdrawn
TroleandomycinThe metabolism of Troleandomycin can be increased when combined with Phenobarbital.Approved
TropatepineThe risk or severity of adverse effects can be increased when Tropatepine is combined with Phenobarbital.Experimental
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Phenobarbital.Approved, Investigational
TropisetronThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Tropisetron.Approved, Investigational
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Phenobarbital.Approved
TubocurarineThe therapeutic efficacy of Phenobarbital can be decreased when used in combination with Tubocurarine.Approved
TyrothricinThe therapeutic efficacy of Phenobarbital can be decreased when used in combination with Tyrothricin.Approved
UdenafilThe metabolism of Udenafil can be increased when combined with Phenobarbital.Approved, Investigational
UlipristalThe serum concentration of Ulipristal can be decreased when it is combined with Phenobarbital.Approved
UmeclidiniumThe risk or severity of adverse effects can be increased when Umeclidinium is combined with Phenobarbital.Approved
UrapidilThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Urapidil.Investigational
Uric AcidThe serum concentration of Uric Acid can be decreased when it is combined with Phenobarbital.Experimental, Investigational
VabicaserinThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Vabicaserin.Investigational
VadimezanThe metabolism of Vadimezan can be increased when combined with Phenobarbital.Investigational
ValaciclovirThe serum concentration of Valaciclovir can be decreased when it is combined with Phenobarbital.Approved, Investigational
ValbenazineThe metabolism of Valbenazine can be increased when combined with Phenobarbital.Approved, Investigational
ValdecoxibThe metabolism of Valdecoxib can be increased when combined with Phenobarbital.Approved, Investigational, Withdrawn
ValerianThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Valerian.Approved, Experimental, Investigational
ValganciclovirThe serum concentration of Valganciclovir can be decreased when it is combined with Phenobarbital.Approved, Investigational
ValinomycinThe serum concentration of Phenobarbital can be increased when it is combined with Valinomycin.Experimental
ValnoctamideThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Valnoctamide.Investigational
ValomaciclovirThe serum concentration of Valomaciclovir can be decreased when it is combined with Phenobarbital.Investigational
Valproic AcidThe serum concentration of Phenobarbital can be increased when it is combined with Valproic Acid.Approved, Investigational
ValpromideThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Valpromide.Experimental
ValsartanPhenobarbital may increase the hypotensive activities of Valsartan.Approved, Investigational
ValspodarThe serum concentration of Phenobarbital can be increased when it is combined with Valspodar.Investigational
VancomycinThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Vancomycin.Approved
VandetanibThe serum concentration of Vandetanib can be decreased when it is combined with Phenobarbital.Approved
VanoxerineThe metabolism of Vanoxerine can be increased when combined with Phenobarbital.Investigational
VardenafilThe metabolism of Vardenafil can be increased when combined with Phenobarbital.Approved
VecuroniumThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Vecuronium.Approved
VelpatasvirThe metabolism of Velpatasvir can be increased when combined with Phenobarbital.Approved, Investigational
VemurafenibThe serum concentration of Vemurafenib can be decreased when it is combined with Phenobarbital.Approved
VenetoclaxThe metabolism of Venetoclax can be increased when combined with Phenobarbital.Approved, Investigational
VenlafaxineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Veralipride.Experimental
VerapamilPhenobarbital may increase the hypotensive activities of Verapamil.Approved
VicrivirocThe metabolism of Vicriviroc can be increased when combined with Phenobarbital.Investigational
VigabatrinThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Vigabatrin.Approved
VilanterolThe metabolism of Vilanterol can be increased when combined with Phenobarbital.Approved
VilazodoneThe serum concentration of Vilazodone can be decreased when it is combined with Phenobarbital.Approved
ViloxazineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Viloxazine.Approved, Investigational, Withdrawn
VinbarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Vinbarbital.Experimental
VinblastineThe metabolism of Vinblastine can be increased when combined with Phenobarbital.Approved
VincristineThe serum concentration of Vincristine can be decreased when it is combined with Phenobarbital.Approved, Investigational
VindesineThe metabolism of Vindesine can be increased when combined with Phenobarbital.Approved, Investigational
VinflunineThe metabolism of Vinflunine can be increased when combined with Phenobarbital.Approved, Investigational
VinorelbineThe metabolism of Vinorelbine can be increased when combined with Phenobarbital.Approved, Investigational
VinpocetineThe metabolism of Vinpocetine can be increased when combined with Phenobarbital.Investigational
Vinyl etherThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Vinyl ether.Experimental
VinylbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Vinylbital.Experimental
VismodegibThe metabolism of Vismodegib can be increased when combined with Phenobarbital.Approved, Investigational
VoacamineThe serum concentration of Phenobarbital can be increased when it is combined with Voacamine.Approved, Investigational
VorapaxarThe serum concentration of Vorapaxar can be decreased when it is combined with Phenobarbital.Approved
VoriconazoleThe serum concentration of Voriconazole can be decreased when it is combined with Phenobarbital.Approved, Investigational
VortioxetineThe serum concentration of Vortioxetine can be decreased when it is combined with Phenobarbital.Approved, Investigational
VoxilaprevirThe metabolism of Voxilaprevir can be increased when combined with Phenobarbital.Approved, Investigational
WarfarinThe metabolism of Warfarin can be increased when combined with Phenobarbital.Approved
WIN 55212-2The metabolism of WIN 55212-2 can be increased when combined with Phenobarbital.Experimental
WortmanninThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Wortmannin.Experimental
XanthineThe serum concentration of Xanthine can be decreased when it is combined with Phenobarbital.Experimental
XP19986The risk or severity of adverse effects can be increased when Phenobarbital is combined with XP19986.Investigational
XylazineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Xylazine.Vet Approved
YKP-1358The risk or severity of adverse effects can be increased when Phenobarbital is combined with YKP-1358.Investigational
YohimbineThe metabolism of Yohimbine can be increased when combined with Phenobarbital.Approved, Investigational, Vet Approved
ZafirlukastThe metabolism of Zafirlukast can be increased when combined with Phenobarbital.Approved, Investigational
ZalcitabineThe metabolism of Zalcitabine can be increased when combined with Phenobarbital.Approved, Investigational
ZaleplonThe serum concentration of Zaleplon can be decreased when it is combined with Phenobarbital.Approved, Illicit, Investigational
ZiconotideThe metabolism of Ziconotide can be increased when combined with Phenobarbital.Approved
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Phenobarbital.Approved
ZileutonThe metabolism of Zileuton can be increased when combined with Phenobarbital.Approved, Investigational, Withdrawn
ZimelidineThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Ziprasidone can be increased when combined with Phenobarbital.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Zolazepam.Vet Approved
ZolmitriptanThe metabolism of Zolmitriptan can be increased when combined with Phenobarbital.Approved, Investigational
ZolpidemPhenobarbital may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZomepiracThe metabolism of Zomepirac can be increased when combined with Phenobarbital.Withdrawn
ZopicloneThe metabolism of Zopiclone can be increased when combined with Phenobarbital.Approved
ZosuquidarThe serum concentration of Phenobarbital can be increased when it is combined with Zosuquidar.Investigational
ZotepineThe metabolism of Zotepine can be increased when combined with Phenobarbital.Approved, Investigational, Withdrawn
ZucapsaicinThe metabolism of Phenobarbital can be decreased when combined with Zucapsaicin.Approved, Investigational
ZuclopenthixolThe serum concentration of Zuclopenthixol can be decreased when it is combined with Phenobarbital.Approved, Investigational
Food Interactions
  • Avoid alcohol.
  • Avoid excessive quantities of coffee or tea (Caffeine).
  • Increase dietary intake of magnesium, folate, vitamin B6, B12, and/or consider taking a multivitamin.
  • Take on an empty stomach for quicker absorption

References

Synthesis Reference

Tong Sun, Shawn Watson, Rajesh Manchanda, "PHENOBARBITAL SALTS; METHODS OF MAKING; AND METHODS OF USE THEREOF." U.S. Patent US20100035904, issued February 11, 2010.

US20100035904
General References
  1. Kwan P, Brodie MJ: Phenobarbital for the treatment of epilepsy in the 21st century: a critical review. Epilepsia. 2004 Sep;45(9):1141-9. [PubMed:15329080]
  2. Taylor S, Tudur Smith C, Williamson PR, Marson AG: Phenobarbitone versus phenytoin monotherapy for partial onset seizures and generalized onset tonic-clonic seizures. Cochrane Database Syst Rev. 2001;(4):CD002217. [PubMed:11687150]
  3. Tudur Smith C, Marson AG, Williamson PR: Carbamazepine versus phenobarbitone monotherapy for epilepsy. Cochrane Database Syst Rev. 2003;(1):CD001904. [PubMed:12535420]
  4. Kalviainen R, Eriksson K, Parviainen I: Refractory generalised convulsive status epilepticus : a guide to treatment. CNS Drugs. 2005;19(9):759-68. [PubMed:16142991]
  5. Booth D, Evans DJ: Anticonvulsants for neonates with seizures. Cochrane Database Syst Rev. 2004 Oct 18;(4):CD004218. [PubMed:15495087]
External Links
Human Metabolome Database
HMDB0015305
KEGG Drug
D00506
KEGG Compound
C07434
PubChem Compound
4763
PubChem Substance
46505776
ChemSpider
4599
BindingDB
50021437
ChEBI
8069
ChEMBL
CHEMBL40
Therapeutic Targets Database
DAP000061
PharmGKB
PA450911
IUPHAR
2804
Guide to Pharmacology
GtP Drug Page
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Phenobarbital
ATC Codes
N03AA02 — PhenobarbitalN05CB01 — Combinations of barbiturates
AHFS Codes
  • 28:12.04 — Barbiturates
  • 28:24.04 — Barbiturates
MSDS
Download (53 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentDrug/Agent Toxicity by Tissue/Organ / Malignant Lymphomas / Neutropenias / Small Intestine Cancer / Unspecified Adult Solid Tumor, Protocol Specific1
1, 2Not Yet RecruitingTreatmentNeonatal Convulsions1
1, 2RecruitingTreatmentNeonatal Convulsions1
2RecruitingTreatmentGeneralized Convulsive Status Epilepticus1
3Active Not RecruitingTreatmentDrug withdrawal syndrome neonatal / Neonatal Opioid Withdrawal1
3CompletedPreventionInfant, Low Birth Weight / Infant, Small for Gestational Age / Infants, Premature / Intracranial Hemorrhages / Newborn Infants1
3CompletedTreatmentDrug withdrawal syndrome neonatal1
3CompletedTreatmentEpilepsies1
3Not Yet RecruitingTreatmentNeonatal Convulsions1
3TerminatedTreatmentAnxiety Disorders / Dementias / Depression / Psychosomatic Disorders / Schizophrenic Disorders1
3WithdrawnTreatmentEpilepsies / Refractory seizure disorders1
4CompletedTreatmentDrug withdrawal syndrome neonatal1
4RecruitingTreatmentNeonatal Convulsions1
4TerminatedTreatmentNeonatal Convulsions1
Not AvailableCompletedNot AvailableEpilepsies1
Not AvailableCompletedNot AvailableNeonatal Convulsions1
Not AvailableNot Yet RecruitingTreatmentAlcohol Withdrawal Delirium / Alcohol Withdrawal Seizures / Alcohol Withdrawal Syndrome(AWS)1
Not AvailableRecruitingNot AvailableEpilepsies1
Not AvailableTerminatedTreatmentDrug withdrawal syndrome neonatal1
Not AvailableWithdrawnTreatmentEpilepsies1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
  • Actavis Group
  • Amend
  • Apotheca Inc.
  • Baxter International Inc.
  • Breckenridge Pharmaceuticals
  • C.O. Truxton Inc.
  • Cardinal Health
  • Carlisle Laboratories Inc.
  • Century Pharmaceuticals Inc.
  • Comprehensive Consultant Services Inc.
  • Direct Dispensing Inc.
  • Dispensing Solutions
  • Diversified Healthcare Services Inc.
  • Econolab Inc.
  • Excellium Pharmaceutical Inc.
  • Group Health Cooperative
  • Heartland Repack Services LLC
  • Hikma Pharmaceuticals
  • Hl Moore Drug Exchange
  • Hospira Inc.
  • Kaiser Foundation Hospital
  • Kraft Pharmaceutical Co. Inc.
  • Lake Erie Medical and Surgical Supply
  • Lundbeck Inc.
  • Major Pharmaceuticals
  • Mallinckrodt Inc.
  • Mckesson Corp.
  • Murfreesboro Pharmaceutical Nursing Supply
  • Nucare Pharmaceuticals Inc.
  • Ohm Laboratories Inc.
  • PD-Rx Pharmaceuticals Inc.
  • Pharmaceutical Association
  • Pharmaceutical Utilization Management Program VA Inc.
  • Pharmacy Service Center
  • Pharmedix
  • Physicians Total Care Inc.
  • Preferred Pharmaceuticals Inc.
  • Prepak Systems Inc.
  • Qualitest
  • Ranbaxy Laboratories
  • Remedy Repack
  • Resource Optimization and Innovation LLC
  • River's Edge Pharmaceuticals
  • Stanley Pharmaceuticals Ltd.
  • UDL Laboratories
  • United Research Laboratories Inc.
  • Vintage Pharmaceuticals Inc.
  • West-Ward Pharmaceuticals
Dosage forms
FormRouteStrength
ElixirOral4 mg
TabletOral
Tablet, extended releaseOral
Tablet, film coated, extended releaseOral
CapsuleOral
TabletOral100 mg
TabletOral15 mg
TabletOral30 mg
TabletOral60 mg
ElixirOral5 mg
ElixirOral20 mg/5mL
LiquidOral20 mg/5mL
TabletOral100 mg/1
TabletOral15 mg/1
TabletOral16.2 mg/1
TabletOral30 mg/1
TabletOral32.4 mg/1
TabletOral60 mg/1
TabletOral64.8 mg/1
TabletOral97.2 mg/1
InjectionIntramuscular; Intravenous130 mg/mL
InjectionIntramuscular; Intravenous65 mg/mL
SolutionIntramuscular; Intravenous; Subcutaneous30 mg
SolutionIntramuscular; Intravenous120 mg
SolutionIntramuscular; Intravenous30 mg
ElixirOral
Prices
Unit descriptionCostUnit
Phenobarbital 130 mg/ml vial4.32USD ml
Phenobarbital 65 mg/ml vial1.63USD ml
Phenobarbital sodium powder0.36USD g
Pms-Phenobarbital 100 mg Tablet0.15USD tablet
Phenobarbital powder0.13USD g
Pms-Phenobarbital 60 mg Tablet0.11USD tablet
Phenobarbital 97.2 mg tablet0.1USD tablet
Phenobarbital 64.8 mg tablet0.09USD tablet
Pms-Phenobarbital 5 mg/ml Elixir0.09USD ml
Phenobarbital 16.2 mg tablet0.08USD tablet
Phenobarbital 30 mg tablet0.08USD tablet
Phenobarbital 32.4 mg tablet0.08USD tablet
Pms-Phenobarbital 30 mg Tablet0.08USD tablet
Phenobarbital 100 mg tablet0.07USD tablet
Pms-Phenobarbital 15 mg Tablet0.07USD tablet
PHENobarbital 20 mg/5ml Elixir0.06USD ml
Phenobarbital 60 mg tablet0.03USD tablet
Phenobarbital 15 mg tablet0.02USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)174 °CPhysProp
water solubility1110 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP1.47HANSCH,C ET AL. (1995)
pKa7.3BUDAVARI,S ET AL. (1996)
Predicted Properties
PropertyValueSource
Water Solubility0.276 mg/mLALOGPS
logP1.4ALOGPS
logP1.41ChemAxon
logS-2.9ALOGPS
pKa (Strongest Acidic)8.14ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area75.27 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity59.75 m3·mol-1ChemAxon
Polarizability22.61 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9935
Blood Brain Barrier+0.9736
Caco-2 permeable-0.5561
P-glycoprotein substrateSubstrate0.5157
P-glycoprotein inhibitor INon-inhibitor0.6472
P-glycoprotein inhibitor IINon-inhibitor0.9869
Renal organic cation transporterNon-inhibitor0.9235
CYP450 2C9 substrateNon-substrate0.6962
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.7702
CYP450 1A2 substrateNon-inhibitor0.84
CYP450 2C9 inhibitorNon-inhibitor0.9023
CYP450 2D6 inhibitorNon-inhibitor0.9593
CYP450 2C19 inhibitorNon-inhibitor0.8664
CYP450 3A4 inhibitorNon-inhibitor0.9236
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9164
Ames testAMES toxic0.9107
CarcinogenicityNon-carcinogens0.7469
BiodegradationNot ready biodegradable0.9894
Rat acute toxicity3.1244 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.99
hERG inhibition (predictor II)Non-inhibitor0.9354
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Download (8.44 KB)
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - EI-BGC-MSsplash10-0udi-5970000000-7bda34bd3bb88b5fd9fd
GC-MS Spectrum - CI-BGC-MSsplash10-001i-0090000000-55265fc1e12027dc6454
Mass Spectrum (Electron Ionization)MSsplash10-0uxr-6950000000-193bf296d3e5d1705628
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-001i-0190000000-8cf53cd66a890256ea98
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-001i-1290000000-73d0e0b25f99ffc6a500
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0016-3950000000-ab62a9483b8a2a65b563
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0006-0900000000-4121e8dd703c01c1161c
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0006-0900000000-4976dfc244184e5d627b
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-001i-1890000000-a12eb2be0b05b9f234de
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-03di-1920000000-43ed71cd16bfceef49e6
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-08fr-2900000000-236ae1dab83b15539a86
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-053u-3900000000-2a994f0e45c022cca640
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-053u-4900000000-066a53ca113150f58406
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-05o3-6900000000-b8f9c9d0f71b6d2c6c2f
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0uy3-8900000000-6bcd457bfff85f05fe9c
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0udi-9500000000-0ecfff7e43e9e78d677e
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0uxs-9300000000-7413ad1c764a1ae4a98e
1H NMR Spectrum1D NMRNot Applicable
13C NMR Spectrum1D NMRNot Applicable

Taxonomy

Description
This compound belongs to the class of organic compounds known as barbituric acid derivatives. These are compounds containing a perhydropyrimidine ring substituted at C-2, -4 and -6 by oxo groups.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Diazines
Sub Class
Pyrimidines and pyrimidine derivatives
Direct Parent
Barbituric acid derivatives
Alternative Parents
N-acyl ureas / Diazinanes / Benzene and substituted derivatives / Dicarboximides / Azacyclic compounds / Organopnictogen compounds / Organonitrogen compounds / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
Substituents
Barbiturate / Ureide / N-acyl urea / Monocyclic benzene moiety / 1,3-diazinane / Benzenoid / Dicarboximide / Urea / Carbonic acid derivative / Carboxylic acid derivative
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
barbiturates (CHEBI:8069)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine...
Gene Name
GABRA1
Uniprot ID
P14867
Uniprot Name
Gamma-aminobutyric acid receptor subunit alpha-1
Molecular Weight
51801.395 Da
References
  1. Whiting PJ: The GABAA receptor gene family: new opportunities for drug development. Curr Opin Drug Discov Devel. 2003 Sep;6(5):648-57. [PubMed:14579514]
  2. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. [PubMed:10209232]
  3. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449]
  4. Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. [PubMed:10487207]
  5. Macdonald RL, McLean MJ: Anticonvulsant drugs: mechanisms of action. Adv Neurol. 1986;44:713-36. [PubMed:2871724]
  6. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  7. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Ligand-gated ion channel activity
Specific Function
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane permeabl...
Gene Name
CHRNA4
Uniprot ID
P43681
Uniprot Name
Neuronal acetylcholine receptor subunit alpha-4
Molecular Weight
69956.47 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449]
  2. Arias HR, Bhumireddy P: Anesthetics as chemical tools to study the structure and function of nicotinic acetylcholine receptors. Curr Protein Pept Sci. 2005 Oct;6(5):451-72. [PubMed:16248797]
  3. Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. [PubMed:10487207]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Toxic substance binding
Specific Function
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane. The cha...
Gene Name
CHRNA7
Uniprot ID
P36544
Uniprot Name
Neuronal acetylcholine receptor subunit alpha-7
Molecular Weight
56448.925 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449]
  2. Arias HR, Bhumireddy P: Anesthetics as chemical tools to study the structure and function of nicotinic acetylcholine receptors. Curr Protein Pept Sci. 2005 Oct;6(5):451-72. [PubMed:16248797]
  3. Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. [PubMed:10487207]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Ionotropic glutamate receptor activity
Specific Function
Receptor for glutamate that functions as ligand-gated ion channel in the central nervous system and plays an important role in excitatory synaptic transmission. L-glutamate acts as an excitatory ne...
Gene Name
GRIA2
Uniprot ID
P42262
Uniprot Name
Glutamate receptor 2
Molecular Weight
98820.32 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449]
  2. Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. [PubMed:10487207]
  3. Jin LJ, Schlesinger F, Song YP, Dengler R, Krampfl K: The interaction of the neuroprotective compounds riluzole and phenobarbital with AMPA-type glutamate receptors: a patch-clamp study. Pharmacology. 2010;85(1):54-62. doi: 10.1159/000268641. Epub 2009 Dec 23. [PubMed:20051697]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Kainate selective glutamate receptor activity
Specific Function
Ionotropic glutamate receptor. L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system. Binding of the excitatory neurotransmitter L-glutamate induces a co...
Gene Name
GRIK2
Uniprot ID
Q13002
Uniprot Name
Glutamate receptor ionotropic, kainate 2
Molecular Weight
102582.475 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449]
  2. Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. [PubMed:10487207]
Kind
Protein group
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Voltage-gated cation channel activity
Specific Function
NMDA receptor subtype of glutamate-gated ion channels with high calcium permeability and voltage-dependent sensitivity to magnesium. Mediated by glycine. This protein plays a key role in synaptic p...

Components:
References
  1. Daniell LC: Effect of anesthetic and convulsant barbiturates on N-methyl-D-aspartate receptor-mediated calcium flux in brain membrane vesicles. Pharmacology. 1994 Nov;49(5):296-307. [PubMed:7862741]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Activator
General Function
Zinc ion binding
Specific Function
Nuclear receptor that binds and is activated by variety of endogenous and xenobiotic compounds. Transcription factor that activates the transcription of multiple genes involved in the metabolism an...
Gene Name
NR1I2
Uniprot ID
O75469
Uniprot Name
Nuclear receptor subfamily 1 group I member 2
Molecular Weight
49761.245 Da
References
  1. Faucette SR, Wang H, Hamilton GA, Jolley SL, Gilbert D, Lindley C, Yan B, Negishi M, LeCluyse EL: Regulation of CYP2B6 in primary human hepatocytes by prototypical inducers. Drug Metab Dispos. 2004 Mar;32(3):348-58. [PubMed:14977870]
  2. Kobayashi K, Yamagami S, Higuchi T, Hosokawa M, Chiba K: Key structural features of ligands for activation of human pregnane X receptor. Drug Metab Dispos. 2004 Apr;32(4):468-72. [PubMed:15039302]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inducer
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Madan A, Graham RA, Carroll KM, Mudra DR, Burton LA, Krueger LA, Downey AD, Czerwinski M, Forster J, Ribadeneira MD, Gan LS, LeCluyse EL, Zech K, Robertson P Jr, Koch P, Antonian L, Wagner G, Yu L, Parkinson A: Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes. Drug Metab Dispos. 2003 Apr;31(4):421-31. [PubMed:12642468]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inducer
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  3. Kawalek JC, Howard KD, Farrell DE, Derr J, Cope CV, Jackson JD, Myers MJ: Effect of oral administration of low doses of pentobarbital on the induction of cytochrome P450 isoforms and cytochrome P450-mediated reactions in immature Beagles. Am J Vet Res. 2003 Sep;64(9):1167-75. [PubMed:13677397]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2B6
Uniprot ID
P20813
Uniprot Name
Cytochrome P450 2B6
Molecular Weight
56277.81 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. Kawalek JC, Howard KD, Farrell DE, Derr J, Cope CV, Jackson JD, Myers MJ: Effect of oral administration of low doses of pentobarbital on the induction of cytochrome P450 isoforms and cytochrome P450-mediated reactions in immature Beagles. Am J Vet Res. 2003 Sep;64(9):1167-75. [PubMed:13677397]
  2. Gerbal-Chaloin S, Pascussi JM, Pichard-Garcia L, Daujat M, Waechter F, Fabre JM, Carrere N, Maurel P: Induction of CYP2C genes in human hepatocytes in primary culture. Drug Metab Dispos. 2001 Mar;29(3):242-51. [PubMed:11181490]
  3. Dvorak Z, Modriansky M, Pichard-Garcia L, Balaguer P, Vilarem MJ, Ulrichova J, Maurel P, Pascussi JM: Colchicine down-regulates cytochrome P450 2B6, 2C8, 2C9, and 3A4 in human hepatocytes by affecting their glucocorticoid receptor-mediated regulation. Mol Pharmacol. 2003 Jul;64(1):160-9. doi: 10.1124/mol.64.1.160. [PubMed:12815172]
  4. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. von Bahr C, Steiner E, Koike Y, Gabrielsson J: Time course of enzyme induction in humans: effect of pentobarbital on nortriptyline metabolism. Clin Pharmacol Ther. 1998 Jul;64(1):18-26. [PubMed:9695715]
  3. Venkatakrishnan K, von Moltke LL, Greenblatt DJ: Nortriptyline E-10-hydroxylation in vitro is mediated by human CYP2D6 (high affinity) and CYP3A4 (low affinity): implications for interactions with enzyme-inducing drugs. J Clin Pharmacol. 1999 Jun;39(6):567-77. [PubMed:10354960]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Sakuma T, Ohtake M, Katsurayama Y, Jarukamjorn K, Nemoto N: Induction of CYP1A2 by phenobarbital in the livers of aryl hydrocarbon-responsive and -nonresponsive mice. Drug Metab Dispos. 1999 Mar;27(3):379-84. [PubMed:10064569]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
Inducer
General Function
Steroid hydroxylase activity
Specific Function
Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Const...
Gene Name
CYP2A6
Uniprot ID
P11509
Uniprot Name
Cytochrome P450 2A6
Molecular Weight
56501.005 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Kawalek JC, Howard KD, Farrell DE, Derr J, Cope CV, Jackson JD, Myers MJ: Effect of oral administration of low doses of pentobarbital on the induction of cytochrome P450 isoforms and cytochrome P450-mediated reactions in immature Beagles. Am J Vet Res. 2003 Sep;64(9):1167-75. [PubMed:13677397]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inducer
General Function
Steroid hydroxylase activity
Specific Function
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic ...
Gene Name
CYP2E1
Uniprot ID
P05181
Uniprot Name
Cytochrome P450 2E1
Molecular Weight
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Leukotriene-b4 20-monooxygenase activity
Specific Function
Catalyzes the omega- and (omega-1)-hydroxylation of various fatty acids such as laurate, myristate and palmitate. Has little activity toward prostaglandins A1 and E1. Oxidizes arachidonic acid to 2...
Gene Name
CYP4A11
Uniprot ID
Q02928
Uniprot Name
Cytochrome P450 4A11
Molecular Weight
59347.31 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Vitamin d 24-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A1
Uniprot ID
P04798
Uniprot Name
Cytochrome P450 1A1
Molecular Weight
58164.815 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1B1
Uniprot ID
Q16678
Uniprot Name
Cytochrome P450 1B1
Molecular Weight
60845.33 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C18
Uniprot ID
P33260
Uniprot Name
Cytochrome P450 2C18
Molecular Weight
55710.075 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A7
Uniprot ID
P24462
Uniprot Name
Cytochrome P450 3A7
Molecular Weight
57525.03 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP4B1
Uniprot ID
P13584
Uniprot Name
Cytochrome P450 4B1
Molecular Weight
58990.64 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Inducer
General Function
Steroid binding
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform glucuronidates bilirubin IX-alpha to form both the...
Gene Name
UGT1A1
Uniprot ID
P22309
Uniprot Name
UDP-glucuronosyltransferase 1-1
Molecular Weight
59590.91 Da
References
  1. Interactions [Link]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inducer
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Schuetz EG, Beck WT, Schuetz JD: Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol Pharmacol. 1996 Feb;49(2):311-8. [PubMed:8632764]
  2. Luna-Tortos C, Fedrowitz M, Loscher W: Several major antiepileptic drugs are substrates for human P-glycoprotein. Neuropharmacology. 2008 Dec;55(8):1364-75. doi: 10.1016/j.neuropharm.2008.08.032. Epub 2008 Sep 11. [PubMed:18824002]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Organic anion transmembrane transporter activity
Specific Function
May act as an inducible transporter in the biliary and intestinal excretion of organic anions. Acts as an alternative route for the export of bile acids and glucuronides from cholestatic hepatocyte...
Gene Name
ABCC3
Uniprot ID
O15438
Uniprot Name
Canalicular multispecific organic anion transporter 2
Molecular Weight
169341.14 Da
References
  1. Kiuchi Y, Suzuki H, Hirohashi T, Tyson CA, Sugiyama Y: cDNA cloning and inducible expression of human multidrug resistance associated protein 3 (MRP3). FEBS Lett. 1998 Aug 14;433(1-2):149-52. [PubMed:9738950]
  2. Cherrington NJ, Slitt AL, Maher JM, Zhang XX, Zhang J, Huang W, Wan YJ, Moore DD, Klaassen CD: Induction of multidrug resistance protein 3 (mrp3) in vivo is independent of constitutive androstane receptor. Drug Metab Dispos. 2003 Nov;31(11):1315-9. [PubMed:14570762]
  3. Slitt AL, Cherrington NJ, Maher JM, Klaassen CD: Induction of multidrug resistance protein 3 in rat liver is associated with altered vectorial excretion of acetaminophen metabolites. Drug Metab Dispos. 2003 Sep;31(9):1176-86. [PubMed:12920174]
  4. Ogawa K, Suzuki H, Hirohashi T, Ishikawa T, Meier PJ, Hirose K, Akizawa T, Yoshioka M, Sugiyama Y: Characterization of inducible nature of MRP3 in rat liver. Am J Physiol Gastrointest Liver Physiol. 2000 Mar;278(3):G438-46. [PubMed:10712264]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Transporter activity
Specific Function
Involved in the ATP-dependent secretion of bile salts into the canaliculus of hepatocytes.
Gene Name
ABCB11
Uniprot ID
O95342
Uniprot Name
Bile salt export pump
Molecular Weight
146405.83 Da
References
  1. Kast HR, Goodwin B, Tarr PT, Jones SA, Anisfeld AM, Stoltz CM, Tontonoz P, Kliewer S, Willson TM, Edwards PA: Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor. J Biol Chem. 2002 Jan 25;277(4):2908-15. Epub 2001 Nov 12. [PubMed:11706036]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Transporter activity
Specific Function
Mediates export of organic anions and drugs from the cytoplasm. Mediates ATP-dependent transport of glutathione and glutathione conjugates, leukotriene C4, estradiol-17-beta-o-glucuronide, methotre...
Gene Name
ABCC1
Uniprot ID
P33527
Uniprot Name
Multidrug resistance-associated protein 1
Molecular Weight
171589.5 Da
References
  1. Kiuchi Y, Suzuki H, Hirohashi T, Tyson CA, Sugiyama Y: cDNA cloning and inducible expression of human multidrug resistance associated protein 3 (MRP3). FEBS Lett. 1998 Aug 14;433(1-2):149-52. [PubMed:9738950]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
May mediate the release of newly synthesized prostaglandins from cells, the transepithelial transport of prostaglandins, and the clearance of prostaglandins from the circulation. Transports PGD2, a...
Gene Name
SLCO2A1
Uniprot ID
Q92959
Uniprot Name
Solute carrier organic anion transporter family member 2A1
Molecular Weight
70043.33 Da
References
  1. Hagenbuch N, Reichel C, Stieger B, Cattori V, Fattinger KE, Landmann L, Meier PJ, Kullak-Ublick GA: Effect of phenobarbital on the expression of bile salt and organic anion transporters of rat liver. J Hepatol. 2001 Jun;34(6):881-7. [PubMed:11451172]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Organic anion transmembrane transporter activity
Specific Function
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name
ABCC2
Uniprot ID
Q92887
Uniprot Name
Canalicular multispecific organic anion transporter 1
Molecular Weight
174205.64 Da
References
  1. Courtois A, Payen L, Le Ferrec E, Scheffer GL, Trinquart Y, Guillouzo A, Fardel O: Differential regulation of multidrug resistance-associated protein 2 (MRP2) and cytochromes P450 2B1/2 and 3A1/2 in phenobarbital-treated hepatocytes. Biochem Pharmacol. 2002 Jan 15;63(2):333-41. [PubMed:11841808]
  2. Schrenk D, Baus PR, Ermel N, Klein C, Vorderstemann B, Kauffmann HM: Up-regulation of transporters of the MRP family by drugs and toxins. Toxicol Lett. 2001 Mar 31;120(1-3):51-7. [PubMed:11323161]
  3. Kast HR, Goodwin B, Tarr PT, Jones SA, Anisfeld AM, Stoltz CM, Tontonoz P, Kliewer S, Willson TM, Edwards PA: Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor. J Biol Chem. 2002 Jan 25;277(4):2908-15. Epub 2001 Nov 12. [PubMed:11706036]
  4. Kauffmann HM, Schrenk D: Sequence analysis and functional characterization of the 5'-flanking region of the rat multidrug resistance protein 2 (mrp2) gene. Biochem Biophys Res Commun. 1998 Apr 17;245(2):325-31. [PubMed:9571149]
  5. Johnson DR, Habeebu SS, Klaassen CD: Increase in bile flow and biliary excretion of glutathione-derived sulfhydryls in rats by drug-metabolizing enzyme inducers is mediated by multidrug resistance protein 2. Toxicol Sci. 2002 Mar;66(1):16-26. [PubMed:11861969]

Drug created on June 13, 2005 07:24 / Updated on August 13, 2018 10:11